Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - GAMG [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - hTERT-RPE1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - JURKAT [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - OE19 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - SuSa [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" "Single Cell Type RNA - Alveolar cells type 1 [NX]" "Single Cell Type RNA - Alveolar cells type 2 [NX]" "Single Cell Type RNA - B-cells [NX]" "Single Cell Type RNA - Basal glandular cells [NX]" "Single Cell Type RNA - Basal keratinocytes [NX]" "Single Cell Type RNA - Bipolar cells [NX]" "Single Cell Type RNA - Cardiomyocytes [NX]" "Single Cell Type RNA - Cholangiocytes [NX]" "Single Cell Type RNA - Ciliated cells [NX]" "Single Cell Type RNA - Club cells [NX]" "Single Cell Type RNA - Collecting duct cells [NX]" "Single Cell Type RNA - Cone photoreceptor cells [NX]" "Single Cell Type RNA - Cytotrophoblasts [NX]" "Single Cell Type RNA - Distal tubular cells [NX]" "Single Cell Type RNA - Ductal cells [NX]" "Single Cell Type RNA - Early spermatids [NX]" "Single Cell Type RNA - Endothelial cells [NX]" "Single Cell Type RNA - Enterocytes [NX]" "Single Cell Type RNA - Erythroid cells [NX]" "Single Cell Type RNA - Exocrine glandular cells [NX]" "Single Cell Type RNA - Extravillous trophoblasts [NX]" "Single Cell Type RNA - Fibroblasts [NX]" "Single Cell Type RNA - Glandular cells [NX]" "Single Cell Type RNA - granulocytes [NX]" "Single Cell Type RNA - Hepatocytes [NX]" "Single Cell Type RNA - Hofbauer cells [NX]" "Single Cell Type RNA - Horizontal cells [NX]" "Single Cell Type RNA - Intestinal endocrine cells [NX]" "Single Cell Type RNA - Ito cells [NX]" "Single Cell Type RNA - Kupffer cells [NX]" "Single Cell Type RNA - Late spermatids [NX]" "Single Cell Type RNA - Leydig cells [NX]" "Single Cell Type RNA - Macrophages [NX]" "Single Cell Type RNA - Melanocytes [NX]" "Single Cell Type RNA - monocytes [NX]" "Single Cell Type RNA - Mucus-secreting cells [NX]" "Single Cell Type RNA - Muller glia cells [NX]" "Single Cell Type RNA - Pancreatic endocrine cells [NX]" "Single Cell Type RNA - Paneth cells [NX]" "Single Cell Type RNA - Peritubular cells [NX]" "Single Cell Type RNA - Proximal tubular cells [NX]" "Single Cell Type RNA - Rod photoreceptor cells [NX]" "Single Cell Type RNA - Sertoli cells [NX]" "Single Cell Type RNA - Smooth muscle cells [NX]" "Single Cell Type RNA - Spermatocytes [NX]" "Single Cell Type RNA - Spermatogonia [NX]" "Single Cell Type RNA - Suprabasal keratinocytes [NX]" "Single Cell Type RNA - Syncytiotrophoblasts [NX]" "Single Cell Type RNA - T-cells [NX]" "Single Cell Type RNA - Undifferentiated cells [NX]" "Single Cell Type RNA - Urothelial cells [NX]" AGRP "Agrt, ART, ASIP2" ENSG00000159723 "Agouti related neuropeptide" O00253 16 67482571-67483813 "Disease related genes, Plasma proteins, Predicted secreted proteins" "Disease mutation, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 19.4;epididymis: 49.8" "Group enriched" "Detected in some" 6 "Distal tubular cells: 3.3;Hofbauer cells: 9.2;Leydig cells: 2.8;Peritubular cells: 2.5" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in some" 13 "hypothalamus: 19.4" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "CACO-2: 2.6;CAPAN-2: 2.8;HeLa: 1.5;Hep G2: 2.2;HMC-1: 1.8" "Region enriched" "Detected in single" 16 "hypothalamus: 18.9" "Region enhanced" "Detected in many" "hypothalamus: 3.9" HPA041017 Enhanced Supported "Secreted in other tissues" NA NA 255000 "HPA041017: AB_10795498" "unprognostic (1.32e-1)" "unprognostic (6.26e-2)" "unprognostic (1.13e-1)" "unprognostic (4.16e-1)" "unprognostic (3.15e-1)" "unprognostic (1.10e-1)" "unprognostic (3.61e-1)" "unprognostic (3.34e-1)" "unprognostic (4.68e-1)" "unprognostic (1.29e-1)" "unprognostic (6.74e-2)" "unprognostic (3.17e-1)" "unprognostic (2.80e-1)" "unprognostic (1.72e-1)" "unprognostic (5.63e-2)" "unprognostic (1.09e-1)" "unprognostic (1.18e-2)" 0.1 9.6 0.1 0.1 1.4 0.0 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.0 0.1 49.8 0.1 0.0 0.1 0.1 0.1 19.4 0.5 0.1 2.1 0.3 0.1 0.3 0.1 0.1 0.0 0.4 0.1 0.2 0.1 0.0 0.3 0.5 0.1 0.1 0.4 0.1 0.1 0.3 0.3 0.1 1.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 2.2 2.1 1.4 3.8 0.3 3.2 1.0 0.1 0.0 0.4 1.4 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.6 2.8 0.8 0.2 0.0 0.3 0.3 0.3 0.0 0.0 0.0 0.0 0.4 1.5 2.2 0.0 0.0 1.8 0.6 0.0 0.0 0.0 0.2 0.0 1.5 0.1 1.0 0.0 0.0 0.2 0.5 0.0 0.2 0.0 0.0 0.0 0.3 0.3 0.7 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.5 0.2 0.0 0.1 1.0 0.5 1.0 0.0 0.4 0.3 0.0 3.8 1.4 3.2 2.3 1.6 2.2 0.8 1.1 1.5 1.9 2.1 2.2 0.6 0.3 1.2 2.1 1.3 1.0 0.1 1.4 0.1 0.2 0.1 19.4 0.1 0.3 0.2 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 9.2 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.8 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 AKR1B1 "ALDR1, AR" ENSG00000085662 "Aldo-keto reductase family 1 member B" P15121 7 134442350-134459284 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "adrenal gland: 302.2;seminal vesicle: 109.3" "Cell type enhanced" "Detected in many" 13 "Collecting duct cells: 615.9;Cytotrophoblasts: 969.9;Extravillous trophoblasts: 1080.2;Syncytiotrophoblasts: 1691.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 122.4;BJ hTERT+: 224.5;RPTEC TERT1: 106.2;U-87 MG: 101.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026425, CAB027391, CAB047353, HPA052751" Enhanced Supported Nucleoplasm,Cytosol No No 1700000 Cytosol Nucleoplasm "CAB027391: , CAB047353: , HPA026425: AB_10601563, HPA052751: AB_2681935" "unprognostic (2.76e-2)" "unprognostic (2.84e-2)" "unprognostic (2.02e-2)" "unprognostic (1.37e-2)" "unprognostic (6.81e-2)" "unprognostic (2.26e-1)" "unprognostic (4.18e-2)" "unprognostic (5.09e-2)" "unprognostic (2.51e-3)" "unprognostic (2.47e-1)" "unprognostic (2.98e-2)" "unprognostic (8.78e-2)" "unprognostic (2.81e-2)" "prognostic unfavorable (2.44e-5)" "unprognostic (2.03e-1)" "unprognostic (1.39e-1)" "prognostic unfavorable (7.00e-4)" 5.9 302.2 7.5 4.7 13.7 2.5 9.5 6.9 10.9 4.4 3.9 8.2 50.4 2.7 4.6 6.1 4.2 4.6 5.2 24.2 7.3 8.4 17.7 2.5 6.9 10.0 9.5 9.0 8.2 7.2 9.4 8.0 24.8 11.9 5.5 4.1 5.8 4.4 109.3 37.6 2.8 4.8 5.6 7.9 6.7 5.0 5.2 5.9 7.3 6.0 10.3 7.6 7.1 3.7 31.4 34.8 22.5 26.0 26.3 42.7 47.2 13.5 122.4 13.8 19.5 59.5 16.2 36.8 13.1 224.5 19.3 25.0 5.6 12.4 0.0 6.1 21.9 85.2 5.7 15.0 13.1 15.4 4.8 13.7 6.9 18.4 16.6 85.3 0.0 0.0 15.1 9.8 27.6 7.3 18.9 27.2 13.6 0.0 4.6 21.3 0.2 20.3 9.3 22.9 0.9 0.1 21.2 8.8 10.2 106.2 66.2 10.3 22.9 91.9 0.1 9.6 9.4 0.0 10.3 21.4 19.1 8.9 1.7 14.2 12.6 13.9 34.2 101.0 0.0 11.4 22.5 26.0 1.2 37.9 17.0 34.0 31.4 32.4 36.7 34.8 28.5 42.7 41.1 2.1 26.3 8.9 4.9 22.0 47.2 7.5 13.7 6.9 10.9 7.3 8.4 9.5 9.0 11.9 5.9 11.9 23.7 50.6 46.4 18.3 34.0 127.0 30.6 24.1 23.9 615.9 7.9 969.9 139.3 102.5 3.0 53.2 0.7 0.0 35.6 1080.2 76.5 15.6 52.0 1.3 331.4 68.3 29.7 89.6 135.4 11.5 73.4 69.6 28.7 93.8 13.6 46.3 62.2 5.8 72.9 43.7 20.2 58.2 30.9 20.7 70.9 10.2 1691.2 45.4 5.0 37.4 ARHGAP36 FLJ30058 ENSG00000147256 "Rho GTPase activating protein 36" Q6ZRI8 X 131058242-131089883 "Predicted intracellular proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 58.4;brain: 25.5;pituitary gland: 50.3" "Not detected" "Not detected" "Cancer enriched" "Detected in some" 21 "thyroid cancer: 62.5" "Region enriched" "Detected in many" 5 "hypothalamus: 25.5" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 164 "SH-SY5Y: 64.4" "Region enhanced" "Detected in many" "hypothalamus: 104.3" "Group enriched" "Detected in many" 5 "basal ganglia: 19.8;hypothalamus: 57.8;midbrain: 27.1;pons and medulla: 20.1" "HPA002064, HPA076209" Enhanced Approved "Nucleoplasm,Vesicles,Plasma membrane" Yes NA Nucleoplasm "Vesicles, Plasma membrane" "HPA002064: AB_1078891, HPA076209: " "unprognostic (2.92e-2)" "unprognostic (7.71e-9)" "unprognostic (2.19e-1)" "unprognostic (8.15e-2)" "unprognostic (1.67e-1)" "unprognostic (1.78e-1)" "unprognostic (2.73e-1)" "unprognostic (1.40e-2)" "unprognostic (1.34e-2)" "unprognostic (2.31e-1)" 6.9 58.4 1.4 0.2 3.6 0.1 1.0 0.0 2.7 0.5 0.2 0.0 0.0 0.1 0.1 2.0 0.3 0.2 0.2 0.1 1.0 25.5 0.1 0.1 0.1 0.1 0.5 0.0 0.1 0.1 0.1 50.3 0.3 5.4 0.3 0.2 0.6 0.2 0.2 13.7 0.1 0.1 0.1 0.8 0.1 0.2 0.6 0.0 0.5 0.5 4.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 64.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 3.6 0.0 0.4 1.0 25.5 0.5 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 AS3MT CYT19 ENSG00000214435 "Arsenite methyltransferase" Q9HBK9 10 102869516-102901899 "Enzymes, Predicted intracellular proteins" "Methyltransferase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 92.8;parathyroid gland: 30.0" "Cell type enhanced" "Detected in single" 20 "Club cells: 1.2" "Cancer enhanced" "Detected in single" "liver cancer: 1.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 6 "NK-cell: 1.4" "Lineage enriched" "Detected in single" 6 "NK-cells: 1.4" "Cell line enhanced" "Detected in many" "AF22: 14.3;REH: 27.2;SH-SY5Y: 14.6;T-47d: 22.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017856 Enhanced Approved Mitochondria NA NA Mitochondria "HPA017856: AB_1847420" "unprognostic (1.11e-1)" "unprognostic (2.02e-4)" "unprognostic (2.45e-1)" "unprognostic (2.25e-1)" "unprognostic (3.39e-1)" "unprognostic (1.66e-1)" "unprognostic (7.02e-4)" "unprognostic (3.22e-1)" "unprognostic (1.42e-1)" "unprognostic (3.90e-2)" "unprognostic (2.03e-1)" "unprognostic (1.83e-1)" "unprognostic (3.83e-10)" "unprognostic (1.04e-2)" "unprognostic (4.17e-2)" "unprognostic (1.59e-1)" "unprognostic (2.16e-2)" 2.0 92.8 3.7 0.7 8.6 0.5 2.6 4.5 6.4 4.0 2.0 2.2 0.4 1.3 3.8 3.2 2.1 2.1 5.2 10.0 5.7 3.1 7.4 22.4 1.7 0.9 2.8 4.4 3.9 8.7 30.0 2.4 0.5 4.6 4.2 0.8 8.9 2.2 3.4 6.0 1.8 1.3 3.9 2.7 5.6 1.7 3.5 1.6 0.3 3.2 1.0 0.7 1.8 1.8 0.0 0.0 0.0 0.0 1.4 0.2 0.0 0.0 3.9 14.3 8.9 0.3 0.3 2.6 4.1 3.5 6.2 7.6 10.6 0.6 0.2 1.2 5.4 0.3 0.2 12.1 0.7 6.4 0.0 3.5 0.0 1.7 10.4 4.1 0.2 0.1 1.9 1.6 0.8 0.0 11.2 0.2 13.2 0.0 0.2 5.5 0.1 2.4 0.3 6.8 0.0 0.6 27.2 0.0 0.1 1.3 0.1 0.4 14.6 0.0 0.2 1.9 4.9 22.7 0.3 0.1 1.3 0.0 2.0 0.0 0.3 0.2 0.0 4.5 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 3.7 8.6 4.5 6.4 5.7 3.1 2.8 4.4 4.6 1.6 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CALY "CALCYON, DRD1IP, NSG3" ENSG00000130643 "Calcyon neuron specific vesicular protein" Q9NYX4 10 133324072-133336935 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "adrenal gland: 26.5;brain: 98.9;pituitary gland: 47.7" "Cell type enhanced" "Detected in some" 19 "Bipolar cells: 84.4;Horizontal cells: 68.3;Intestinal endocrine cells: 18.7;Rod photoreceptor cells: 31.1" "Group enriched" "Detected in some" 14 "glioma: 1.7;pancreatic cancer: 7.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.3;naive CD4 T-cell: 1.0" "Lineage enriched" "Detected in single" 14 "T-cells: 1.3" "Cell line enhanced" "Detected in some" "SH-SY5Y: 2.7;U-266/70: 2.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042283 Enhanced NA NA "HPA042283: AB_10794417" "unprognostic (1.43e-2)" "unprognostic (7.84e-2)" "unprognostic (3.77e-3)" "unprognostic (1.41e-2)" "unprognostic (7.32e-2)" "unprognostic (9.81e-3)" "unprognostic (2.56e-1)" "unprognostic (7.48e-2)" "unprognostic (1.36e-1)" "unprognostic (1.18e-1)" "prognostic favorable (3.54e-4)" "unprognostic (1.23e-2)" "unprognostic (4.19e-10)" "unprognostic (8.04e-3)" "unprognostic (1.29e-1)" "unprognostic (3.60e-1)" "unprognostic (1.63e-1)" 1.8 26.5 27.1 2.7 57.4 1.8 1.8 12.7 67.1 1.7 2.6 3.6 0.0 5.0 1.7 1.9 1.8 2.0 1.8 1.7 31.8 98.9 1.7 1.7 1.9 2.0 25.1 39.8 1.7 6.3 1.7 47.7 1.7 33.9 1.8 2.4 0.7 2.1 2.0 1.7 1.9 3.8 2.1 14.3 1.9 4.1 4.3 4.8 0.0 1.9 0.0 1.9 1.7 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.6 0.1 0.8 0.3 0.0 0.0 0.0 0.3 0.6 0.6 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.2 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.8 1.1 0.0 1.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.1 1.0 0.0 1.1 0.0 0.0 0.3 0.3 0.0 0.0 0.4 0.1 0.0 0.0 0.0 2.7 0.0 0.0 0.9 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.1 2.7 0.0 0.0 0.3 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 27.1 57.4 12.7 45.9 31.8 98.9 25.1 39.8 33.9 4.8 0.0 0.0 0.0 0.0 0.2 84.4 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.1 68.3 18.7 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 8.1 0.9 0.0 0.4 0.2 31.1 0.0 0.8 1.4 2.6 0.0 0.2 0.0 0.0 0.0 CARTPT CART ENSG00000164326 "CART prepropeptide" Q16568 5 71719163-71721048 "FDA approved drug targets, Predicted secreted proteins" "Neuropeptide, Neurotransmitter" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "adrenal gland: 67.5;brain: 101.4" "Cell type enhanced" "Detected in some" 12 "Bipolar cells: 5.8;Cone photoreceptor cells: 7.9;Early spermatids: 12.3;Glandular cells: 4.8;Intestinal endocrine cells: 6.8;Rod photoreceptor cells: 7.6" "Cancer enriched" "Detected in many" 9 "breast cancer: 117.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "NB-4: 1.1;SH-SY5Y: 3.5" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "hippocampal formation: 179.9" "CAB025515, HPA046278, CAB079776" Enhanced Supported "Secreted to blood" NA NA "CAB025515: , CAB079776: , HPA046278: AB_10961570" "unprognostic (1.37e-1)" "unprognostic (1.43e-1)" "unprognostic (2.27e-1)" "unprognostic (3.45e-2)" "unprognostic (6.67e-2)" "prognostic unfavorable (4.36e-4)" "unprognostic (1.14e-1)" 1.6 67.5 8.0 2.8 22.3 0.5 5.8 0.1 29.0 0.5 3.4 2.1 0.0 3.5 0.6 0.9 3.5 0.7 0.6 0.5 31.1 101.4 0.5 0.5 0.5 0.5 1.0 4.5 0.5 5.3 0.5 1.7 0.5 54.1 3.3 3.1 1.6 0.5 0.5 0.5 0.5 1.4 8.1 8.6 0.5 3.4 1.9 9.7 0.0 3.4 0.0 0.5 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 22.3 0.1 29.0 31.1 101.4 1.0 4.5 54.1 9.7 0.0 0.0 0.0 0.3 0.0 5.8 0.0 0.0 0.0 0.0 0.0 7.9 0.0 0.0 0.0 12.3 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 6.8 0.0 0.0 2.7 0.6 0.0 0.0 0.0 0.0 2.3 0.0 0.0 1.1 0.0 7.6 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.1 CHGB "SCG1, SgI" ENSG00000089199 "Chromogranin B" P05060 20 5911430-5925361 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 424.9;pituitary gland: 177.5" "Cell type enriched" "Detected in many" 11 "Intestinal endocrine cells: 997.5" "Cancer enriched" "Detected in many" 6 "pancreatic cancer: 154.2" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 2.6;T-reg: 1.1" "Lineage enhanced" "Detected in single" "T-cells: 2.6" "Group enriched" "Detected in some" 23 "SCLC-21H: 66.7;SH-SY5Y: 102.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008759, CAB009403, HPA012602" Enhanced Supported Enhanced Vesicles "Intracellular and membrane" NA NA 24000000 Vesicles "CAB009403: AB_2081255, HPA008759: AB_1846704, HPA012602: AB_1846706" "unprognostic (1.79e-3)" "unprognostic (7.72e-2)" "unprognostic (3.48e-1)" "unprognostic (2.90e-2)" "unprognostic (1.68e-2)" "prognostic unfavorable (1.89e-4)" "unprognostic (7.96e-3)" "unprognostic (2.86e-1)" "unprognostic (6.18e-3)" "unprognostic (7.93e-2)" "prognostic favorable (9.96e-4)" "unprognostic (8.56e-2)" "unprognostic (8.21e-2)" "unprognostic (1.56e-1)" "unprognostic (2.81e-2)" "unprognostic (2.73e-1)" "unprognostic (1.01e-2)" 3.4 424.9 8.2 1.4 10.2 0.8 1.0 82.5 16.4 0.8 3.0 2.1 1.2 7.7 0.9 1.3 0.8 2.5 0.8 7.6 20.7 15.4 1.7 0.7 1.0 1.1 7.2 9.1 3.0 17.0 0.8 177.5 0.8 51.8 5.6 2.5 0.7 0.9 1.2 2.1 0.9 4.4 0.9 2.3 0.8 19.7 2.4 0.8 0.0 1.9 0.4 0.9 0.8 0.1 0.0 0.6 0.0 0.0 0.0 2.6 0.2 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.2 0.0 0.7 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 3.6 0.2 0.0 0.0 0.0 0.0 0.1 0.0 66.7 102.1 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 1.1 0.0 0.6 0.0 0.1 0.4 0.1 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.1 0.2 8.2 10.2 82.5 16.4 20.7 15.4 7.2 9.1 51.8 0.8 3.0 3.7 0.0 8.2 3.8 86.9 51.2 0.0 8.1 1.2 66.3 19.6 0.0 1.7 0.4 6.1 3.4 1.7 0.0 0.3 0.0 2.3 2.3 0.0 0.0 0.1 71.5 997.5 0.0 0.3 6.0 0.9 1.5 6.8 1.8 2.8 9.3 37.4 5.8 0.4 0.1 49.6 12.9 1.4 50.2 27.7 3.1 0.2 0.0 1.4 3.0 CPLX1 CPX-I ENSG00000168993 "Complexin 1" O14810 4 784957-826198 "Predicted intracellular proteins" "Exocytosis, Neurotransmitter transport, Transport" "Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 13 "brain: 98.8" "Cell type enhanced" "Detected in many" 9 "Bipolar cells: 30.5;Horizontal cells: 17.5;Intestinal endocrine cells: 20.6;Rod photoreceptor cells: 15.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 2.3" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in some" 5 "SCLC-21H: 43.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA071191, HPA074390" Supported Uncertain Vesicles NA NA Vesicles "HPA071191: , HPA074390: " "unprognostic (9.21e-3)" "prognostic unfavorable (4.20e-4)" "unprognostic (3.45e-2)" "unprognostic (4.68e-2)" "unprognostic (1.16e-2)" "unprognostic (1.02e-1)" "unprognostic (3.14e-2)" "unprognostic (2.26e-2)" "unprognostic (9.52e-3)" "unprognostic (2.01e-2)" "prognostic favorable (5.05e-4)" "unprognostic (1.10e-3)" "unprognostic (3.32e-1)" "unprognostic (2.05e-2)" "unprognostic (1.12e-1)" "unprognostic (1.34e-1)" "unprognostic (7.77e-2)" 7.8 6.5 13.1 2.9 40.7 1.5 2.4 26.3 98.8 2.2 2.5 3.9 0.0 2.8 4.2 1.5 1.6 2.3 1.9 3.0 16.9 7.6 2.4 2.4 2.8 2.4 16.3 18.3 2.4 3.0 3.4 1.7 1.8 52.8 4.4 1.7 3.8 4.4 2.5 4.5 3.0 2.8 2.0 5.4 5.6 3.2 4.9 4.2 0.0 1.8 0.0 1.6 1.7 1.7 0.2 2.3 0.1 0.0 0.0 0.8 0.0 2.7 0.2 0.0 0.4 0.0 0.0 0.2 0.1 0.0 0.0 0.0 8.2 0.9 2.0 0.9 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.9 0.2 0.0 0.8 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 1.1 0.9 0.1 0.0 1.2 1.1 0.0 1.3 2.2 1.3 0.0 0.0 0.8 0.0 0.2 43.0 6.0 0.2 2.8 0.0 0.1 4.3 0.1 0.0 0.0 0.3 0.0 0.0 0.1 2.2 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.3 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 13.1 40.7 26.3 98.8 16.9 7.6 16.3 18.3 52.8 4.2 0.0 0.0 0.0 3.4 0.9 30.5 3.0 0.0 0.0 3.4 0.0 3.9 0.0 1.7 0.4 1.2 10.8 0.5 0.0 0.7 2.6 0.7 2.0 0.0 3.8 0.2 17.5 20.6 8.0 0.3 1.9 1.7 0.0 1.7 0.0 1.7 13.7 0.7 2.9 0.0 0.8 15.0 0.0 1.4 4.7 8.2 1.0 0.8 1.0 1.5 1.1 CPLX2 "CPX-2, DKFZp547D155" ENSG00000145920 "Complexin 2" Q6PUV4 5 175796310-175884020 "Predicted intracellular proteins" "Differentiation, Exocytosis, Mast cell degranulation, Neurogenesis, Neurotransmitter transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 95.3;epididymis: 80.1" "Cell type enhanced" "Detected in some" 29 "Horizontal cells: 90.6;Intestinal endocrine cells: 35.2;Late spermatids: 18.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 4 "MAIT T-cell: 1.2" "Lineage enriched" "Detected in single" 13 "T-cells: 1.2" "Group enriched" "Detected in some" 22 "A549: 106.1;Hep G2: 64.0;SCLC-21H: 45.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA071191, HPA074390" Supported Uncertain Vesicles NA NA Vesicles "HPA071191: , HPA074390: " "unprognostic (1.36e-1)" "unprognostic (1.12e-1)" "unprognostic (2.81e-1)" "unprognostic (8.98e-2)" "unprognostic (1.23e-2)" "unprognostic (5.73e-2)" "unprognostic (5.16e-2)" "unprognostic (2.49e-3)" "unprognostic (6.22e-2)" "unprognostic (1.20e-2)" "unprognostic (2.06e-1)" "unprognostic (1.90e-5)" "unprognostic (6.88e-2)" "unprognostic (2.20e-1)" "unprognostic (7.32e-2)" "unprognostic (6.87e-2)" 1.7 23.3 72.6 2.0 32.7 1.4 1.3 79.0 95.3 1.3 2.6 2.6 0.3 2.7 1.3 80.1 1.4 1.4 1.4 1.3 68.3 16.3 1.4 1.3 2.1 1.3 37.2 26.3 1.3 7.9 1.3 11.3 1.3 17.9 1.4 2.2 0.2 1.3 1.4 1.3 1.4 2.5 1.6 4.0 1.3 5.1 3.1 3.7 0.0 1.4 0.0 1.3 1.5 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 106.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 64.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 2.6 0.0 0.0 0.0 0.1 0.0 0.0 45.2 3.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 72.6 32.7 79.0 66.6 68.3 16.3 37.2 26.3 17.9 3.7 0.0 0.0 0.0 0.0 0.0 3.6 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 90.6 35.2 0.0 0.0 18.1 0.9 0.0 0.0 0.0 0.0 0.8 0.3 0.0 0.0 0.0 3.8 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 CYP11A1 "CYP11A, P450SCC" ENSG00000140459 "Cytochrome P450 family 11 subfamily A member 1" P05108 15 74337759-74367740 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Steroidogenesis, Sterol metabolism" "Monooxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 145.3;placenta: 157.2" "Group enriched" "Detected in some" 5 "Extravillous trophoblasts: 305.6;Syncytiotrophoblasts: 1214.3" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in single" 36 "basal ganglia: 14.8" "Cell type enriched" "Detected in single" 37 "basophil: 15.8" "Lineage enriched" "Detected in single" 37 "granulocytes: 15.8" "Group enriched" "Detected in some" 4 "BEWO: 44.0;HEL: 35.0" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA016436 Enhanced NA NA "HPA016436: AB_1847423" "unprognostic (8.89e-2)" "unprognostic (6.96e-2)" "unprognostic (4.95e-3)" "unprognostic (9.31e-2)" "unprognostic (9.42e-4)" "unprognostic (1.90e-1)" "unprognostic (1.55e-3)" "unprognostic (8.06e-2)" "unprognostic (3.04e-1)" "unprognostic (2.95e-1)" "unprognostic (1.77e-2)" "unprognostic (5.45e-2)" "unprognostic (9.66e-4)" "unprognostic (2.40e-2)" "unprognostic (2.74e-1)" "unprognostic (3.04e-2)" "unprognostic (7.95e-2)" 0.4 145.3 0.4 0.1 14.8 0.0 0.4 0.3 0.3 0.2 0.2 7.6 0.1 0.0 0.3 0.5 1.5 0.3 0.0 0.3 0.3 0.2 0.1 0.7 0.1 0.0 0.3 0.2 9.2 0.1 0.0 0.4 157.2 0.2 0.2 0.0 0.3 0.1 0.6 0.3 0.1 0.1 0.3 0.3 5.7 0.1 20.4 0.1 0.0 0.1 0.3 0.7 0.2 0.2 0.0 0.0 15.8 0.0 0.4 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.3 44.0 0.1 0.0 0.3 0.1 0.0 0.0 0.0 1.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.1 35.0 1.0 0.3 0.2 0.0 0.2 1.5 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 8.9 0.0 0.0 6.9 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 15.8 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.4 14.8 0.3 0.3 0.3 0.2 0.3 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.4 2.5 0.0 0.0 0.0 0.0 139.8 1.7 0.0 1.4 0.0 0.0 0.0 0.0 305.6 0.6 0.1 0.0 3.4 19.4 0.0 0.0 0.0 0.0 2.9 45.1 0.0 0.0 1.0 0.0 5.1 0.2 0.0 163.4 0.0 0.0 0.0 0.0 3.2 3.1 0.0 1214.3 0.0 0.0 0.0 CYP11B1 "CPN1, CYP11B, FHI, P450C11" ENSG00000160882 "Cytochrome P450 family 11 subfamily B member 1" P15538 8 142872356-142879846 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroidogenesis" "Monooxygenase, Oxidoreductase" "Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 781 "adrenal gland: 224.9" "Group enriched" "Detected in some" 119 "Early spermatids: 41.1;Late spermatids: 67.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "SCLC-21H: 3.1;SH-SY5Y: 1.3" "HPA049171, HPA056348, HPA057752" Supported NA NA "HPA049171: AB_2680661, HPA056348: AB_2683104, HPA057752: AB_2683516" 0.0 224.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 41.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 67.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 CYP11B2 "ALDOS, CPN2, CYP11B, CYP11BL, P-450C18, P450aldo" ENSG00000179142 "Cytochrome P450 family 11 subfamily B member 2" P19099 8 142910559-142917843 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Lipid metabolism, Steroid metabolism, Steroidogenesis" "Monooxygenase, Oxidoreductase" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 259 "adrenal gland: 51.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049171, HPA056348, HPA057752" Supported NA NA "HPA049171: AB_2680661, HPA056348: AB_2683104, HPA057752: AB_2683516" 0.0 51.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CYP17A1 "CPT7, CYP17, P450C17, S17AH" ENSG00000148795 "Cytochrome P450 family 17 subfamily A member 1" P05093 10 102830531-102837533 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Steroidogenesis "Lyase, Monooxygenase, Oxidoreductase" "Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "adrenal gland: 425.4" "Cell type enhanced" "Detected in some" 17 "Distal tubular cells: 18.3;Early spermatids: 40.8;Proximal tubular cells: 39.5" "Cancer enriched" "Detected in many" 5 "liver cancer: 22.7" "Region enriched" "Detected in single" 103 "basal ganglia: 19.7" "Cell type enhanced" "Detected in single" "neutrophil: 1.2" "Lineage enhanced" "Detected in single" "granulocytes: 1.2" "Group enriched" "Detected in some" 4 "HMC-1: 8.0;SCLC-21H: 3.1" "Not detected" "Not detected" "Not detected" "Not detected" HPA048533 Enhanced "Intracellular and membrane" NA NA "HPA048533: AB_2680432" "unprognostic (1.07e-2)" "unprognostic (8.84e-2)" "unprognostic (3.01e-2)" "unprognostic (9.08e-2)" "unprognostic (1.91e-1)" "unprognostic (6.29e-2)" "unprognostic (2.92e-3)" "unprognostic (2.39e-4)" "unprognostic (8.26e-2)" "unprognostic (2.35e-1)" "unprognostic (5.92e-3)" "unprognostic (1.13e-1)" "prognostic favorable (5.43e-7)" "unprognostic (1.07e-1)" "unprognostic (5.56e-2)" "unprognostic (1.66e-2)" "unprognostic (2.94e-4)" 0.0 425.4 0.0 0.1 19.7 0.0 0.0 0.1 0.1 0.1 0.0 78.5 0.0 0.0 0.1 0.3 0.1 0.1 0.0 0.1 0.0 0.0 6.4 1.7 0.1 0.0 0.0 0.0 3.2 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 82.3 0.0 0.1 2.2 0.0 0.0 0.1 0.0 0.0 0.0 1.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 8.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.3 0.0 0.0 0.0 0.0 0.1 0.1 3.1 1.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.2 0.0 0.0 0.0 0.0 19.7 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.3 0.1 0.6 0.6 0.0 0.0 0.0 1.8 0.0 0.3 18.3 0.0 40.8 0.0 0.0 0.0 0.2 0.0 0.2 0.2 0.0 3.2 0.1 1.6 0.0 0.0 0.0 8.3 1.7 0.2 0.0 0.0 0.0 0.2 1.2 0.0 0.0 39.5 1.3 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.1 CYP21A2 "CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B" ENSG00000231852 "Cytochrome P450 family 21 subfamily A member 2" P08686 6 32038265-32041670 "Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" Steroidogenesis "Monooxygenase, Oxidoreductase" "Congenital adrenal hyperplasia, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 23 "adrenal gland: 170.9" "Cell type enriched" "Detected in some" 6 "Hepatocytes: 14.4" "Cancer enhanced" "Detected in some" "liver cancer: 2.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HDLM-2: 11.8;Hep G2: 1.9;Karpas-707: 3.2" "Not detected" "Not detected" "HPA048979, HPA053371" Enhanced "Intracellular and membrane" NA NA "HPA048979: AB_2680584, HPA053371: AB_2682131" "unprognostic (1.03e-2)" "unprognostic (1.65e-1)" "unprognostic (1.02e-4)" "unprognostic (2.58e-1)" "unprognostic (2.97e-1)" "unprognostic (2.93e-2)" "unprognostic (2.76e-2)" "unprognostic (8.75e-2)" "unprognostic (1.39e-1)" "unprognostic (1.71e-1)" "unprognostic (1.41e-1)" "unprognostic (1.93e-1)" "unprognostic (6.67e-7)" "unprognostic (7.39e-2)" "unprognostic (5.24e-2)" "unprognostic (1.09e-1)" "unprognostic (1.82e-1)" 0.1 170.9 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 6.7 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.3 7.4 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 3.6 0.0 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 11.8 0.3 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 1.1 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.3 0.3 2.5 1.4 1.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.3 1.1 14.4 0.0 0.0 1.7 0.0 0.0 0.0 0.6 0.0 1.7 0.0 0.0 0.2 0.5 0.0 0.0 1.7 0.4 0.0 0.2 0.5 0.4 0.0 0.0 0.0 0.0 0.0 DBH DBM ENSG00000123454 "Dopamine beta-hydroxylase" P09172 9 133636360-133659344 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Catecholamine biosynthesis" "Monooxygenase, Oxidoreductase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "adrenal gland: 86.6;brain: 36.2;liver: 35.6" "Cell type enriched" "Detected in single" 43 "Ito cells: 17.2" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 45 "pons and medulla: 36.2" "Cell type enhanced" "Detected in single" "naive CD4 T-cell: 2.0" "Lineage enriched" "Detected in single" 21 "T-cells: 2.0" "Cell line enriched" "Detected in single" 340 "SH-SY5Y: 206.1" "Region enriched" "Detected in some" 6 "pons and medulla: 23.2" "Region enriched" "Detected in single" 38 "pons and medulla: 25.1" "HPA002130, HPA005960, HPA070789" Enhanced Supported "Endoplasmic reticulum,Vesicles" "Intracellular and membrane" NA NA 2000000000 Vesicles "Endoplasmic reticulum" "HPA002130: AB_2666554, HPA005960: AB_1078628, HPA070789: AB_2686312" "unprognostic (1.93e-3)" "unprognostic (7.52e-3)" "unprognostic (8.53e-2)" "unprognostic (2.10e-2)" "unprognostic (2.18e-3)" "unprognostic (3.38e-3)" "unprognostic (3.39e-3)" "unprognostic (3.97e-2)" "unprognostic (1.71e-1)" "unprognostic (8.99e-2)" "unprognostic (5.80e-2)" "unprognostic (7.69e-2)" "unprognostic (2.81e-7)" "unprognostic (9.31e-2)" "unprognostic (6.77e-2)" "unprognostic (1.49e-2)" "unprognostic (5.06e-3)" 0.7 86.6 0.1 0.3 0.1 0.0 0.0 0.1 0.8 0.3 0.0 1.9 0.7 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.5 35.6 0.3 0.6 0.0 0.0 0.1 1.3 0.0 0.6 0.4 36.2 0.8 0.0 1.0 0.2 5.9 0.0 0.0 0.2 0.0 1.4 0.4 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.8 0.5 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.6 0.5 0.0 0.0 0.2 206.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.8 0.0 0.1 0.0 0.0 36.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 DLK1 "Delta1, FA1, pG2, Pref-1, ZOG" ENSG00000185559 "Delta like non-canonical Notch ligand 1" P80370 14 100725705-100738224 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 157.6;pituitary gland: 143.1;placenta: 244.9" "Group enriched" "Detected in many" 5 "Exocrine glandular cells: 527.9;Leydig cells: 1256.4" "Cancer enhanced" "Detected in many" "liver cancer: 28.1" "Group enriched" "Detected in some" 5 "hypothalamus: 2.6;pons and medulla: 6.0" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "AF22: 23.1;Hep G2: 77.0;SH-SY5Y: 91.7" "Region enhanced" "Detected in some" "hypothalamus: 65.4" "Region enhanced" "Detected in many" "midbrain: 159.6" "CAB005872, HPA062262" Enhanced Approved "Golgi apparatus" NA NA 160000 "Golgi apparatus" "CAB005872: AB_731965, HPA062262: AB_2684729" "unprognostic (2.16e-2)" "prognostic unfavorable (2.31e-4)" "unprognostic (1.49e-1)" "unprognostic (1.14e-1)" "unprognostic (4.89e-3)" "unprognostic (5.75e-2)" "unprognostic (1.87e-2)" "unprognostic (1.12e-1)" "unprognostic (5.24e-1)" "unprognostic (3.11e-2)" "unprognostic (6.57e-2)" 0.3 157.6 0.2 0.7 0.8 0.0 0.9 0.0 0.1 0.5 0.0 1.8 0.2 0.2 0.2 4.4 0.3 0.3 0.8 2.7 0.1 2.6 0.1 0.1 0.1 0.1 0.8 0.0 34.9 4.6 0.0 143.1 244.9 6.0 0.2 0.0 0.2 8.2 0.0 2.0 0.1 0.2 0.2 0.3 0.2 0.2 14.2 0.0 0.5 0.0 10.0 1.3 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 23.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.3 0.0 77.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.1 6.5 91.7 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.2 0.8 0.0 0.0 0.1 2.6 0.8 0.0 6.0 0.0 0.0 0.0 0.0 0.2 0.6 0.0 3.2 0.0 0.0 0.0 0.0 0.0 52.1 0.0 2.9 4.0 0.0 0.0 0.0 527.9 35.4 1.3 0.5 0.0 0.0 73.1 0.0 0.0 0.0 0.0 11.5 1256.4 0.0 0.0 0.0 0.0 0.0 6.5 0.0 162.3 0.0 0.0 58.2 0.0 6.5 56.6 0.4 88.4 0.0 0.0 0.1 DPYSL2 "CRMP2, DHPRP2, DRP-2, DRP2" ENSG00000092964 "Dihydropyrimidinase like 2" Q16555 8 26514022-26658178 "Plasma proteins, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 137.0" "Cell type enhanced" "Detected in many" 5 "Ito cells: 240.0" "Cancer enhanced" "Detected in all" "glioma: 89.3" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 24.0;intermediate monocyte: 26.7;myeloid DC: 25.5;non-classical monocyte: 16.2;plasmacytoid DC: 15.1" "Group enriched" "Detected in many" 6 "dendritic cells: 25.5;monocytes: 26.7" "Cell line enhanced" "Detected in many" "ASC diff: 61.4;Karpas-707: 63.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002381, CAB018719" Supported Supported "Plasma membrane,Cytosol" NA NA 3900000 Cytosol "Plasma membrane" "CAB018719: AB_2085366, HPA002381: AB_1847244" "unprognostic (2.88e-2)" "unprognostic (1.01e-2)" "unprognostic (9.51e-2)" "unprognostic (3.16e-3)" "unprognostic (8.23e-2)" "unprognostic (1.68e-2)" "unprognostic (1.51e-1)" "unprognostic (9.95e-3)" "unprognostic (5.48e-2)" "unprognostic (1.39e-1)" "unprognostic (1.79e-2)" "unprognostic (4.13e-2)" "unprognostic (5.58e-2)" "unprognostic (9.32e-3)" "unprognostic (1.23e-1)" "unprognostic (3.27e-2)" "prognostic unfavorable (5.41e-5)" 31.6 21.7 53.5 13.4 48.1 3.0 21.3 51.8 137.0 14.6 12.2 54.7 3.9 7.1 14.2 8.1 12.0 14.7 18.0 27.2 52.9 48.6 12.1 11.2 45.3 9.9 56.5 45.4 25.8 7.5 5.1 7.2 25.6 46.9 9.8 12.4 8.2 6.5 10.3 10.9 10.2 9.7 19.9 70.1 19.0 8.5 7.5 44.9 5.8 7.7 5.2 12.3 14.0 13.1 3.2 25.5 0.6 26.7 4.0 4.6 8.8 4.7 23.1 22.8 12.1 61.4 28.3 2.2 9.3 21.8 8.9 11.6 9.0 6.9 7.1 6.8 29.2 18.0 4.6 23.9 9.3 8.5 16.1 2.0 8.1 8.8 12.6 39.4 1.7 3.3 35.1 13.5 24.4 14.2 28.8 17.9 5.6 0.2 63.2 8.9 3.0 13.7 1.7 17.8 15.3 4.5 18.3 9.1 4.7 15.0 5.5 10.4 21.9 11.3 0.1 6.1 15.7 1.7 3.2 32.2 20.3 8.2 16.8 4.0 8.9 9.1 5.6 29.4 10.6 10.3 0.4 24.0 0.2 3.5 26.7 1.2 3.2 3.1 2.3 25.5 1.7 1.6 2.1 0.6 4.0 16.2 15.1 4.6 8.8 53.5 48.1 51.8 68.4 52.9 48.6 56.5 45.4 46.9 44.9 122.1 67.9 17.3 0.8 35.8 104.6 86.8 104.4 17.4 31.8 21.0 29.5 12.9 3.3 17.3 2.6 134.9 3.1 0.0 1.6 9.2 59.6 1.1 19.7 13.4 46.2 133.5 58.3 240.0 207.1 6.4 100.9 92.1 114.7 101.8 73.9 141.1 9.7 3.6 84.1 17.3 36.8 135.8 60.8 3.1 8.5 29.5 3.8 8.7 6.6 1.1 ELAVL4 "HUD, PNEM" ENSG00000162374 "ELAV like RNA binding protein 4" P26378 1 50048014-50203786 "Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 43.1" "Group enriched" "Detected in some" 11 "Early spermatids: 111.8;Intestinal endocrine cells: 31.6;Late spermatids: 117.9" "Group enriched" "Detected in some" 10 "glioma: 2.6;pancreatic cancer: 0.6;testis cancer: 0.5" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 1.4;non-classical monocyte: 3.1" "Lineage enriched" "Detected in single" 5 "monocytes: 3.1" "Cell line enriched" "Detected in some" 19 "SH-SY5Y: 53.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004442, HPA043047" Enhanced Approved Nucleoplasm,Vesicles NA NA "Nucleoplasm, Vesicles" "CAB004442: AB_627765, HPA043047: AB_2732502" "unprognostic (1.25e-1)" "unprognostic (6.63e-3)" "unprognostic (4.43e-2)" "unprognostic (1.13e-1)" "unprognostic (1.95e-1)" "unprognostic (3.28e-2)" "unprognostic (3.83e-4)" "unprognostic (4.52e-2)" "unprognostic (2.63e-1)" "unprognostic (2.75e-1)" "unprognostic (3.75e-3)" "unprognostic (7.91e-2)" "unprognostic (2.39e-3)" "unprognostic (7.83e-2)" "unprognostic (2.81e-2)" "unprognostic (4.13e-2)" "unprognostic (7.43e-2)" 0.9 11.4 11.5 3.3 12.8 0.8 1.0 11.6 43.1 0.9 3.0 0.9 0.0 2.3 0.9 0.8 1.1 0.9 1.0 1.0 12.3 16.5 0.9 1.0 1.0 0.9 10.6 30.7 0.8 2.8 0.8 7.1 0.9 37.0 1.0 3.8 0.0 0.9 0.9 0.8 1.2 3.1 2.0 8.5 1.0 1.9 7.8 1.4 0.1 0.8 0.0 1.0 0.9 0.5 0.0 0.6 0.0 3.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 53.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 3.1 0.6 0.0 0.0 11.5 12.8 11.6 40.4 12.3 16.5 10.6 30.7 37.0 1.4 0.0 0.0 0.0 0.0 0.7 0.8 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 111.8 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.1 0.0 31.6 0.0 4.5 117.9 1.4 2.3 1.7 0.0 0.0 1.0 0.5 0.0 0.4 0.0 3.0 0.0 0.0 7.5 7.9 0.6 0.1 0.0 0.0 0.0 ELOVL5 "dJ483K16.1, HELO1, SCA38" ENSG00000012660 "ELOVL fatty acid elongase 5" Q9NYP7 6 53267398-53349179 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" Transferase "Disease mutation, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Glandular cells: 250.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017042, HPA047752, HPA054197" Enhanced Enhanced "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "CAB017042: , HPA047752: AB_2680147, HPA054197: AB_2682413" "unprognostic (7.33e-2)" "unprognostic (5.80e-2)" "unprognostic (1.04e-1)" "unprognostic (1.92e-2)" "unprognostic (1.16e-1)" "unprognostic (5.01e-2)" "unprognostic (3.06e-1)" "unprognostic (2.19e-1)" "unprognostic (4.38e-2)" "unprognostic (1.43e-2)" "unprognostic (3.23e-1)" "unprognostic (6.40e-2)" "prognostic unfavorable (1.94e-6)" "unprognostic (1.58e-1)" "unprognostic (5.12e-2)" "prognostic unfavorable (6.80e-4)" "unprognostic (2.76e-2)" 75.7 48.7 17.9 24.2 22.0 33.9 78.8 13.3 22.1 18.2 13.9 38.3 91.2 9.7 15.7 18.0 10.8 16.5 18.0 14.6 18.3 17.5 13.5 36.8 24.4 33.6 41.1 12.3 13.1 5.7 8.1 11.6 13.6 26.4 45.2 6.7 16.1 9.4 88.4 3.6 11.4 17.3 18.0 46.4 18.5 9.5 34.8 29.1 28.7 17.6 5.6 33.6 16.6 19.4 23.8 18.1 60.7 11.3 8.4 25.3 10.4 25.3 18.5 32.5 59.3 86.2 50.1 13.8 29.6 33.3 23.9 33.6 16.4 29.4 28.8 21.5 30.7 37.6 15.0 32.0 27.1 35.9 24.2 22.5 28.4 17.3 22.8 47.4 22.4 20.8 46.2 21.3 23.9 30.1 24.2 26.5 57.5 35.4 16.8 17.2 2.7 66.5 19.9 17.5 0.9 14.2 26.0 22.3 10.0 45.0 15.2 30.3 20.8 24.5 12.8 24.8 22.1 29.2 21.0 25.1 26.3 23.4 46.8 38.9 14.1 13.0 21.9 13.7 32.6 18.6 9.0 11.3 40.7 8.8 8.1 14.2 21.6 14.7 10.6 18.1 23.8 7.2 6.7 60.7 8.4 9.6 4.8 25.3 10.4 17.9 22.0 13.3 20.2 18.3 17.5 41.1 12.3 26.4 29.1 74.5 46.1 107.2 78.7 46.5 7.7 20.2 22.9 49.5 31.8 12.2 2.0 21.5 13.3 32.0 79.1 51.7 5.1 0.0 31.8 46.1 52.2 250.9 98.0 83.9 32.1 7.9 24.0 41.1 61.4 135.1 19.2 53.0 45.5 16.2 0.6 75.7 19.7 0.6 30.1 34.2 5.2 64.7 88.4 20.7 10.4 53.2 26.1 87.3 4.3 62.0 ESR2 "ER-beta, Erb, NR3A2" ENSG00000140009 "Estrogen receptor 2" Q92731 14 64084232-64338112 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 19.1;testis: 30.2;vagina: 14.3" "Group enriched" "Detected in many" 9 "Early spermatids: 48.9;Late spermatids: 62.8;Rod photoreceptor cells: 41.7" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "Karpas-707: 4.1;U-266/70: 10.8;U-698: 17.6" "Low region specificity" "Detected in some" "Region enriched" "Detected in many" 5 "cerebellum: 17.8" CAB079300 Enhanced NA NA "CAB079300: " "unprognostic (7.63e-3)" "unprognostic (2.28e-3)" "unprognostic (8.27e-3)" "unprognostic (5.41e-2)" "unprognostic (2.91e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (4.38e-2)" "unprognostic (1.95e-1)" "unprognostic (8.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.65e-1)" "unprognostic (3.03e-5)" "unprognostic (1.57e-1)" "unprognostic (1.66e-1)" "unprognostic (4.21e-2)" "unprognostic (5.89e-2)" 2.1 9.4 0.2 2.3 0.8 1.0 3.7 0.8 0.6 1.3 2.9 0.6 0.2 1.4 1.7 0.7 1.7 1.1 0.6 1.0 1.1 0.4 1.4 0.7 1.3 2.8 0.2 0.2 19.1 2.5 0.0 1.6 0.7 1.4 2.2 1.5 0.5 1.5 0.9 1.4 1.2 1.5 0.6 1.0 3.0 1.3 30.2 0.6 5.0 0.6 0.2 2.9 1.8 14.3 2.4 4.0 1.1 0.3 0.4 1.3 0.2 0.7 0.3 0.7 0.7 0.0 0.1 1.3 0.1 0.0 0.1 0.1 0.2 0.8 2.9 0.1 0.0 0.3 1.0 0.9 0.0 0.1 0.7 0.3 0.3 0.7 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.2 0.2 0.3 1.2 0.6 4.1 0.2 0.7 0.4 0.2 0.7 0.6 0.4 0.5 0.4 0.3 0.1 1.4 2.5 0.7 0.5 0.2 1.1 0.4 0.8 0.0 0.4 0.5 1.0 0.2 0.1 10.8 3.2 17.6 0.2 0.1 0.7 0.3 0.3 1.0 0.8 0.2 0.6 1.7 0.6 1.1 0.1 2.4 1.3 1.0 1.1 0.4 0.2 4.0 0.5 0.2 0.2 0.8 0.8 0.6 1.1 0.4 0.2 0.2 1.4 0.6 6.0 0.0 2.7 2.5 0.2 1.4 0.8 0.0 2.7 1.2 0.0 5.9 0.6 0.0 0.1 48.9 0.6 0.0 0.0 0.6 0.4 0.3 0.9 1.1 0.0 0.1 0.0 0.0 0.0 0.0 62.8 0.9 0.0 1.7 0.0 0.6 1.6 0.4 0.0 1.1 0.0 41.7 0.0 0.8 6.0 0.8 0.1 0.9 0.5 0.4 1.7 FDX1 "ADX, FDX" ENSG00000137714 "Ferredoxin 1" P10109 11 110429883-110464881 "Predicted intracellular proteins" "Cholesterol metabolism, Electron transport, Lipid metabolism, Steroid metabolism, Steroidogenesis, Sterol metabolism, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 113.9;seminal vesicle: 55.6" "Cell type enhanced" "Detected in all" 11 "Syncytiotrophoblasts: 953.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 38.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA041630, HPA062087" Enhanced Enhanced Mitochondria NA NA Mitochondria "HPA041630: AB_10793970, HPA062087: AB_2630366" "unprognostic (1.66e-1)" "unprognostic (1.68e-2)" "unprognostic (5.29e-3)" "unprognostic (4.67e-2)" "unprognostic (2.39e-1)" "unprognostic (4.32e-3)" "unprognostic (1.23e-2)" "unprognostic (2.07e-1)" "unprognostic (2.19e-2)" "unprognostic (4.12e-1)" "unprognostic (3.10e-2)" "unprognostic (5.48e-2)" "prognostic favorable (3.58e-7)" "prognostic favorable (2.53e-4)" "unprognostic (1.10e-1)" "unprognostic (1.94e-1)" "unprognostic (2.80e-1)" 5.5 113.9 3.9 4.7 4.5 3.9 5.6 2.7 4.0 3.2 7.5 5.2 33.7 7.9 3.2 3.9 5.1 3.0 5.6 9.6 3.6 4.3 10.7 22.8 7.8 4.7 4.5 2.5 3.5 8.6 3.5 3.7 48.4 3.1 4.8 4.2 4.2 4.1 55.6 7.3 3.3 12.3 3.6 3.4 3.9 5.0 5.3 2.6 5.2 8.7 5.0 3.5 5.6 5.4 10.7 6.9 3.4 5.8 4.4 8.7 2.9 5.4 3.8 5.8 6.4 5.7 10.2 13.1 5.0 6.1 4.4 7.5 12.9 9.1 12.7 14.8 6.4 7.9 6.4 6.8 7.5 6.1 12.1 8.6 6.4 6.7 7.9 10.1 6.7 10.5 17.7 6.3 4.0 9.6 7.7 9.0 8.8 6.4 18.9 9.4 6.0 9.5 14.9 5.2 10.3 7.2 14.0 5.6 11.7 9.6 9.8 8.0 4.1 9.5 10.9 6.3 7.1 6.4 4.6 5.3 4.5 5.5 5.4 5.3 4.3 3.3 38.1 3.4 13.7 5.7 1.8 5.7 3.4 5.3 4.2 5.8 10.7 7.3 7.4 6.9 7.5 8.6 6.1 0.7 4.4 5.8 5.3 8.7 2.9 3.9 4.5 2.7 4.0 3.6 4.3 4.5 2.5 3.1 2.6 17.9 39.7 88.0 75.8 60.8 27.9 46.0 104.4 6.7 9.1 76.8 7.9 144.7 207.2 62.6 22.7 33.8 131.1 46.7 128.1 138.7 46.5 71.9 46.0 160.8 108.7 39.7 46.0 33.7 54.7 7.0 43.4 60.1 65.8 51.3 45.4 26.2 79.9 67.0 42.8 255.2 15.0 25.8 42.6 41.2 70.7 85.2 953.0 57.5 77.9 120.2 FDXR ADXR ENSG00000161513 "Ferredoxin reductase" P22570 17 74862497-74873031 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cholesterol metabolism, Electron transport, Lipid metabolism, Steroid metabolism, Sterol metabolism, Transport" Oxidoreductase "Deafness, Disease mutation, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 93.9" "Cell type enhanced" "Detected in many" 5 "Cytotrophoblasts: 47.2;Syncytiotrophoblasts: 38.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 30.1;Hep G2: 55.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008597, CAB009818, HPA044393, HPA053673" Enhanced Enhanced Mitochondria NA NA Mitochondria "CAB008597: AB_1615557, CAB009818: AB_2102601, HPA044393: AB_2678927, HPA053673: AB_2682225" "unprognostic (2.69e-2)" "unprognostic (1.17e-3)" "unprognostic (7.51e-2)" "prognostic favorable (2.38e-4)" "unprognostic (3.43e-2)" "unprognostic (1.20e-1)" "unprognostic (1.53e-1)" "unprognostic (1.68e-2)" "unprognostic (2.29e-1)" "unprognostic (1.50e-1)" "unprognostic (1.09e-1)" "unprognostic (6.30e-2)" "unprognostic (1.42e-2)" "unprognostic (1.19e-2)" "unprognostic (4.50e-2)" "unprognostic (4.03e-2)" "unprognostic (2.13e-1)" 1.7 93.9 2.6 2.1 3.1 1.3 1.8 8.4 2.7 2.1 4.6 3.2 6.4 2.6 2.6 23.8 8.7 6.6 6.1 1.9 3.4 1.7 2.7 4.1 4.4 1.7 2.9 3.5 7.1 3.9 2.3 1.5 2.6 3.6 3.3 2.1 0.9 5.3 4.2 7.9 5.6 2.5 2.0 4.4 9.7 2.2 32.1 3.0 3.9 2.0 7.7 3.7 3.0 3.0 5.4 7.4 4.8 6.4 10.0 15.2 5.6 4.0 21.6 3.2 3.6 2.3 3.1 30.1 4.8 5.3 2.9 5.8 6.0 3.5 9.6 0.8 2.0 1.6 8.3 2.3 6.0 0.8 9.1 5.0 7.3 3.5 55.1 6.5 1.6 25.5 10.1 6.8 3.0 1.0 2.3 14.7 3.6 11.5 1.6 4.4 17.1 6.2 3.3 1.8 3.8 4.7 3.4 5.4 5.1 2.4 6.8 1.7 4.0 3.3 7.2 3.5 3.8 15.7 1.5 6.8 2.0 17.9 3.1 2.4 4.4 0.7 2.1 5.4 2.5 6.7 1.8 6.4 4.8 6.2 4.3 5.3 5.4 5.6 7.3 7.4 2.8 4.9 6.1 2.1 10.0 3.2 1.4 15.2 5.6 2.6 3.1 8.4 2.7 3.4 1.7 2.9 3.5 3.6 3.0 3.0 4.6 3.7 12.8 8.7 4.9 3.4 5.1 21.4 5.7 8.7 3.9 47.2 5.0 9.7 5.2 2.8 14.8 0.0 6.8 14.1 6.1 4.3 5.7 12.5 18.6 3.2 6.8 12.3 4.6 12.2 5.5 3.6 5.0 3.6 10.8 10.9 8.3 21.0 4.2 16.3 4.9 0.0 6.4 7.1 7.6 15.8 38.6 8.5 17.6 13.1 FGF11 "FHF3, FLJ16061, MGC102953, MGC45269" ENSG00000161958 "Fibroblast growth factor 11" Q92914 17 7438273-7444937 "Predicted intracellular proteins" "Growth factor" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "adrenal gland: 23.5" "Cell type enhanced" "Detected in many" 10 "Horizontal cells: 17.5;Muller glia cells: 12.7;Suprabasal keratinocytes: 8.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "eosinophil: 1.6" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "A-431: 9.4;HaCaT: 17.3;LHCN-M2: 11.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA066605, HPA075188" Enhanced Approved Centrosome NA NA Centrosome "HPA066605: AB_2685693, HPA075188: AB_2732283" "unprognostic (7.35e-2)" "unprognostic (1.14e-2)" "unprognostic (7.67e-3)" "unprognostic (2.79e-4)" "unprognostic (9.15e-2)" "unprognostic (3.28e-2)" "unprognostic (7.31e-2)" "unprognostic (3.11e-2)" "unprognostic (1.59e-2)" "unprognostic (1.45e-1)" "unprognostic (4.69e-2)" "unprognostic (2.89e-3)" "unprognostic (2.00e-6)" "unprognostic (1.12e-1)" "unprognostic (2.30e-1)" "unprognostic (6.90e-3)" "unprognostic (4.97e-3)" 3.3 23.5 10.5 3.0 13.8 2.1 2.9 4.5 11.6 6.4 1.6 4.6 0.1 1.8 3.1 1.9 13.0 1.7 3.2 11.6 11.7 4.6 3.4 1.1 1.3 6.2 8.1 5.2 1.6 1.3 1.5 1.0 2.0 10.6 1.4 1.4 6.8 3.7 1.7 8.8 19.7 1.3 2.9 4.1 2.4 1.6 2.8 9.9 2.5 7.2 7.1 9.0 2.9 8.7 0.0 0.0 1.6 0.6 0.0 0.3 0.0 9.4 0.6 5.3 0.0 3.1 0.1 2.7 0.2 3.3 0.3 0.6 0.2 1.0 2.8 0.7 0.1 0.1 17.3 2.0 5.4 1.2 5.9 4.2 5.2 0.5 1.3 0.5 0.2 5.8 0.6 1.5 0.4 0.2 0.5 0.2 2.2 2.0 0.2 11.4 2.1 1.7 2.3 1.9 0.4 0.2 4.5 4.8 1.2 0.7 0.8 1.1 5.4 0.6 0.6 0.4 3.1 0.3 0.4 0.2 0.3 5.7 0.0 0.2 0.4 1.3 0.9 1.3 3.2 0.6 0.0 0.0 1.6 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.3 0.0 10.5 13.8 4.5 11.6 11.7 4.6 8.1 5.2 10.6 9.9 0.0 0.0 0.0 0.3 4.8 2.8 0.4 2.5 0.0 0.0 1.8 5.9 0.3 3.3 0.5 1.3 0.8 0.4 0.0 0.2 0.4 0.4 0.5 0.0 0.0 0.3 17.5 0.0 0.6 0.3 3.4 1.7 0.3 1.7 0.0 0.3 12.7 1.0 0.0 2.1 0.1 2.5 0.0 0.9 1.2 1.3 8.4 0.6 0.0 0.6 0.9 HCN4 ENSG00000138622 "Hyperpolarization activated cyclic nucleotide gated potassium channel 4" Q9Y3Q4 15 73319859-73369264 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Sodium transport, Transport" "Ion channel, Ligand-gated ion channel, Potassium channel, Sodium channel, Voltage-gated channel" "Brugada syndrome, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 4.3;heart muscle: 12.5;testis: 9.6" "Group enriched" "Detected in some" 7 "Early spermatids: 28.7;Late spermatids: 33.9" "Group enriched" "Detected in some" 8 "testis cancer: 3.1;thyroid cancer: 0.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 2.6;CACO-2: 3.2;HDLM-2: 2.1;NTERA-2: 9.5;SuSa: 2.5;U-2 OS: 4.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA073174 Approved NA NA "HPA073174: " "unprognostic (2.21e-1)" "unprognostic (1.39e-1)" "unprognostic (2.18e-2)" "unprognostic (3.14e-2)" "unprognostic (5.30e-3)" "unprognostic (1.92e-2)" "unprognostic (2.19e-1)" "unprognostic (3.50e-2)" "unprognostic (2.37e-1)" "unprognostic (6.56e-2)" "unprognostic (1.13e-3)" "unprognostic (1.13e-1)" "unprognostic (6.05e-5)" "unprognostic (5.56e-2)" "unprognostic (4.60e-2)" "unprognostic (1.51e-2)" "unprognostic (7.95e-2)" 0.2 1.3 4.3 0.2 1.1 0.1 0.1 0.9 3.4 0.2 0.4 2.1 0.0 1.2 0.1 0.2 0.1 0.3 0.2 12.5 0.6 2.0 0.4 0.1 0.3 0.1 1.8 0.9 0.1 0.2 0.1 2.1 0.1 3.9 0.6 0.3 0.2 0.1 1.0 0.1 0.2 0.4 0.2 0.7 0.1 0.6 9.6 1.9 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.2 0.0 1.5 0.0 0.6 0.2 0.0 0.0 0.1 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.1 0.0 0.5 0.0 0.0 2.5 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 1.1 0.9 3.4 0.6 2.0 1.8 0.9 3.9 1.9 0.0 0.0 0.0 0.0 0.0 0.5 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 28.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 33.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.0 1.2 0.0 0.1 0.6 1.3 0.0 0.0 0.0 0.0 0.0 HSD3B1 "HSD3B, HSDB3, SDR11E1" ENSG00000203857 "Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1" P14060 1 119507198-119515054 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Steroid metabolism, Steroidogenesis" "Isomerase, Multifunctional enzyme, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 19 "placenta: 231.4" "Group enriched" "Detected in some" 23 "Extravillous trophoblasts: 115.9;Syncytiotrophoblasts: 419.8" "Cancer enhanced" "Detected in single" "urothelial cancer: 1.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "CACO-2: 36.4;SuSa: 16.3" "HPA043261, HPA043264, HPA044028" Supported Approved "Nucleoli,Endoplasmic reticulum,Cytokinetic bridge" NA NA "Nucleoli, Endoplasmic reticulum" "Cytokinetic bridge" "HPA043261: AB_2630368, HPA043264: AB_2678398, HPA044028: AB_2678781" "unprognostic (1.53e-1)" "unprognostic (7.11e-2)" "unprognostic (1.15e-1)" "unprognostic (1.04e-1)" "prognostic favorable (4.59e-5)" 0.1 0.6 0.0 0.0 0.3 0.0 0.7 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.1 0.5 0.0 0.0 231.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 4.5 11.9 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 36.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 4.0 0.4 0.5 16.3 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.5 0.0 0.0 0.0 0.0 0.7 0.0 0.0 115.9 0.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 419.8 0.0 0.0 0.0 HSD3B2 SDR11E2 ENSG00000203859 "Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2" P26439 1 119414931-119423035 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Steroidogenesis "Isomerase, Multifunctional enzyme, Oxidoreductase" "Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "adrenal gland: 223.2" "Cell type enhanced" "Detected in some" 17 "Enterocytes: 1.6;Exocrine glandular cells: 1.1;Peritubular cells: 2.5" "Cancer enhanced" "Detected in single" "testis cancer: 0.6" "Region enriched" "Detected in single" 198 "basal ganglia: 19.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "SCLC-21H: 1.5;SH-SY5Y: 1.4;SK-MEL-30: 5.1;SuSa: 1.9;TIME: 1.2;WM-115: 3.2" "HPA043261, HPA043264, HPA044028" Supported Uncertain "Nucleoli,Endoplasmic reticulum,Cytokinetic bridge" NA NA "Nucleoli, Endoplasmic reticulum" "Cytokinetic bridge" "HPA043261: AB_2630368, HPA043264: AB_2678398, HPA044028: AB_2678781" "unprognostic (3.56e-1)" "unprognostic (1.85e-1)" "unprognostic (2.80e-1)" "unprognostic (2.72e-2)" "unprognostic (8.87e-2)" "unprognostic (3.91e-2)" "unprognostic (3.43e-2)" "unprognostic (1.94e-1)" "unprognostic (6.51e-2)" "unprognostic (1.97e-2)" "unprognostic (1.55e-1)" 0.0 223.2 0.0 0.8 19.8 0.0 0.0 0.0 0.0 0.0 0.5 43.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 3.6 0.2 0.0 0.0 0.0 1.9 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.5 1.4 0.0 0.0 5.1 1.9 0.0 0.0 1.2 0.2 0.1 0.1 0.7 0.0 0.0 0.0 0.8 0.0 3.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.6 0.0 1.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.5 0.0 2.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 HTR4 5-HT4 ENSG00000164270 "5-hydroxytryptamine receptor 4" Q13639 5 148451032-148677235 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "brain: 18.1;heart muscle: 7.2;intestine: 14.6;pituitary gland: 5.9" "Cell type enhanced" "Detected in some" 18 "Cardiomyocytes: 4.3;Enterocytes: 2.8;Undifferentiated cells: 3.5" "Not detected" "Not detected" "Region enhanced" "Detected in many" "basal ganglia: 18.1" "Cell type enriched" "Detected in single" 8 "T-reg: 1.5" "Lineage enriched" "Detected in single" 15 "T-cells: 1.5" "Cell line enriched" "Detected in single" 5 "Karpas-707: 2.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA040591 Enhanced NA NA "HPA040591: AB_2677028" "unprognostic (1.12e-1)" "unprognostic (4.60e-2)" "unprognostic (7.74e-2)" "unprognostic (2.37e-1)" "unprognostic (5.02e-2)" "unprognostic (3.77e-2)" "unprognostic (4.68e-2)" "unprognostic (1.10e-2)" "unprognostic (1.13e-1)" "unprognostic (1.46e-1)" "unprognostic (3.40e-2)" "unprognostic (2.25e-1)" "unprognostic (4.49e-2)" "unprognostic (8.83e-5)" 0.4 1.4 1.9 1.1 18.1 0.1 0.2 0.1 3.2 0.6 4.3 0.0 0.0 8.0 0.3 0.1 0.3 0.4 1.5 7.2 5.2 0.6 0.1 0.2 0.3 0.2 0.5 1.3 0.2 0.1 0.1 5.9 0.1 0.1 0.1 4.9 0.0 0.2 0.2 0.2 0.2 14.6 1.1 0.3 0.2 0.2 0.2 2.4 0.0 0.2 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.5 0.0 1.9 18.1 0.1 3.2 5.2 0.6 0.5 1.3 0.1 2.4 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 MC2R ACTHR ENSG00000185231 "Melanocortin 2 receptor" Q01718 18 13882044-13915707 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adrenal gland: 31.7;pituitary gland: 14.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "basophil: 1.3" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.3" "Cell line enhanced" "Detected in some" "HeLa: 1.7;MCF7: 3.6;SuSa: 1.8" "Not detected" "Not detected" "Not detected" "Not detected" HPA079148 Enhanced NA NA "HPA079148: " "unprognostic (2.09e-1)" "unprognostic (3.63e-2)" "unprognostic (1.85e-2)" 0.0 31.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 14.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.1 0.0 0.0 0.3 0.0 0.1 0.1 1.3 0.3 0.1 0.1 0.0 0.2 0.0 0.1 0.3 0.1 0.3 1.1 0.2 0.0 0.1 0.3 0.1 0.2 0.0 0.0 0.4 0.1 0.3 0.1 0.9 0.1 0.0 0.5 0.0 1.7 0.2 0.0 0.2 0.0 0.0 0.9 0.0 0.6 0.2 0.0 0.2 0.1 0.4 0.0 3.6 0.0 0.0 0.6 0.0 0.1 0.2 0.5 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.1 1.8 0.1 0.3 0.0 0.2 0.3 0.5 0.0 0.2 0.2 0.0 0.1 0.4 0.0 1.3 0.1 0.0 0.1 0.3 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.5 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MGARP "C4orf49, CESP-1, HUMMR, OSAP" ENSG00000137463 "Mitochondria localized glutamic acid rich protein" Q8TDB4 4 139266163-139280338 "Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 88.9;retina: 30.7" "Group enriched" "Detected in some" 9 "Bipolar cells: 140.5;Horizontal cells: 197.0;Muller glia cells: 424.1" "Cancer enhanced" "Detected in some" "renal cancer: 4.1" "Group enriched" "Detected in many" 4 "basal ganglia: 4.5;cerebellum: 8.0" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 1.7;naive CD4 T-cell: 1.6" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "BJ: 10.7;fHDF/TERT166: 15.9;HHSteC: 12.9;HUVEC TERT2: 32.4" "Low region specificity" "Detected in some" "HPA015994, HPA070835" Enhanced Supported Mitochondria NA NA Mitochondria "HPA015994: AB_2630370, HPA070835: " "unprognostic (2.68e-1)" "unprognostic (1.73e-1)" "unprognostic (8.18e-2)" "unprognostic (4.25e-2)" "unprognostic (3.54e-2)" "unprognostic (3.11e-2)" "unprognostic (3.42e-2)" "unprognostic (1.02e-3)" "unprognostic (2.90e-2)" "unprognostic (4.96e-2)" "unprognostic (1.50e-2)" "unprognostic (1.31e-1)" "unprognostic (4.08e-2)" "unprognostic (1.47e-2)" "unprognostic (9.91e-2)" "unprognostic (2.09e-2)" "unprognostic (2.36e-1)" 3.2 88.9 1.0 0.5 4.5 0.4 1.2 8.0 1.2 3.6 1.0 2.1 1.1 0.4 2.6 3.0 0.5 0.8 1.3 6.1 0.8 1.4 1.0 0.4 0.5 0.6 1.0 0.0 20.1 0.5 0.4 15.3 0.5 1.5 2.0 0.5 30.7 0.4 2.0 0.6 0.5 0.4 2.3 0.7 0.6 0.4 5.9 0.5 0.0 0.5 0.0 0.5 2.1 1.0 0.5 0.0 0.0 0.3 0.5 1.7 0.3 0.0 0.5 0.3 0.2 0.8 0.4 0.0 10.7 0.0 1.6 0.0 0.0 0.1 0.0 0.1 15.9 4.6 0.2 2.3 0.0 0.9 0.0 1.0 0.0 0.0 0.1 12.9 0.1 0.1 3.9 0.3 1.7 0.1 3.8 32.4 0.1 0.2 0.2 2.6 0.0 0.4 0.2 0.6 0.2 0.0 0.0 0.0 0.0 0.3 0.1 0.3 0.6 0.0 0.0 0.1 0.2 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.4 0.3 0.3 4.5 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 1.7 0.4 0.0 0.3 1.6 0.7 0.0 0.5 0.2 0.0 0.3 0.3 1.0 4.5 8.0 1.2 0.8 1.4 1.0 0.0 1.5 0.5 0.0 0.0 0.0 0.7 1.4 140.5 2.5 0.0 0.0 0.0 0.0 7.9 0.2 1.7 0.0 0.2 0.2 0.0 0.0 0.0 0.1 2.4 0.3 0.0 0.0 0.5 197.0 0.0 0.6 0.0 0.0 15.8 0.0 0.0 0.0 0.0 424.1 0.1 0.0 23.3 7.6 28.7 0.0 0.4 0.7 0.3 0.6 0.2 0.0 0.0 0.3 NOV "CCN3, IGFBP9" ENSG00000136999 "Nephroblastoma overexpressed" P48745 8 119416306-119424353 "Plasma proteins, Predicted secreted proteins, Transporters" "Growth factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "adrenal gland: 236.7" "Cell type enhanced" "Detected in many" 14 "Collecting duct cells: 36.6;granulocytes: 23.1;Melanocytes: 74.2" "Cancer enhanced" "Detected in all" "melanoma: 62.7" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 113 "eosinophil: 28.1;neutrophil: 14.0" "Lineage enriched" "Detected in single" 151 "granulocytes: 28.1" "Cell line enhanced" "Detected in many" "BJ hTERT+: 43.7;hTERT-RPE1: 13.6;U-2197: 45.2" "Group enriched" "Detected in many" 7 "amygdala: 134.6;basal ganglia: 51.6;cerebral cortex: 101.0;hippocampal formation: 166.1" "Low region specificity" "Detected in many" "HPA018449, HPA019684, CAB034423" Enhanced Enhanced Vesicles "Secreted to blood" NA NA 269000000 2900000 Vesicles "CAB034423: AB_2151387, HPA018449: AB_1846189, HPA019684: AB_1846190" "unprognostic (5.04e-2)" "unprognostic (1.01e-1)" "unprognostic (7.36e-3)" "unprognostic (1.30e-3)" "unprognostic (9.35e-3)" "unprognostic (4.92e-1)" "unprognostic (8.10e-2)" "unprognostic (6.04e-2)" "unprognostic (1.79e-2)" "unprognostic (9.17e-2)" "unprognostic (1.67e-1)" "unprognostic (3.10e-1)" "unprognostic (2.66e-1)" "unprognostic (8.74e-3)" "unprognostic (1.51e-1)" "unprognostic (1.98e-1)" "unprognostic (2.72e-2)" 6.3 236.7 2.2 1.4 7.9 1.0 5.6 3.1 12.3 5.0 2.0 3.6 3.6 1.5 5.8 2.9 1.9 3.0 2.0 5.7 3.5 1.9 4.9 0.9 2.9 1.1 2.1 15.1 1.8 2.7 2.1 13.4 0.8 7.4 5.6 2.2 1.2 1.2 5.0 1.6 3.6 1.5 2.5 2.5 1.0 1.6 2.6 0.0 0.0 6.9 4.8 1.1 3.3 2.5 0.0 0.1 28.1 0.1 0.0 0.0 0.0 0.0 1.0 0.6 0.0 4.0 1.0 0.0 5.8 43.7 5.3 3.0 0.0 0.1 0.0 4.6 7.3 4.1 3.6 0.2 0.0 1.8 0.0 0.1 0.0 3.4 0.0 0.1 0.0 0.0 0.2 0.0 2.0 0.2 13.6 0.1 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.4 8.7 0.0 0.0 0.0 5.6 0.0 1.3 0.0 2.1 0.0 8.1 0.0 0.0 0.0 0.0 3.8 5.8 45.2 1.2 0.0 0.0 0.0 6.0 1.8 4.3 0.0 0.1 28.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 14.0 0.0 0.0 0.0 0.0 0.0 2.2 7.9 3.1 12.3 3.5 1.9 2.1 15.1 7.4 0.0 0.0 1.1 0.0 0.6 16.7 0.0 1.2 0.0 2.7 2.3 36.6 0.0 0.0 0.0 7.2 0.0 12.6 0.3 0.0 1.0 0.0 15.4 14.0 23.1 0.0 1.4 3.2 9.2 0.6 1.2 0.0 2.8 0.4 74.2 0.0 1.3 0.0 0.6 2.9 0.7 0.0 0.2 0.0 20.8 0.0 0.0 14.8 0.1 0.0 9.8 0.9 NPTX2 ENSG00000106236 "Neuronal pentraxin 2" P47972 7 98617297-98629868 "Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "adrenal gland: 24.0;brain: 45.6;pancreas: 19.5;pituitary gland: 71.6;testis: 20.7" "Group enriched" "Detected in many" 6 "Peritubular cells: 306.6;Sertoli cells: 148.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "plasmacytoid DC: 1.5" "Lineage enriched" "Detected in single" 16 "dendritic cells: 1.5" "Cell line enriched" "Detected in some" 12 "LHCN-M2: 128.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB020801, HPA049799, HPA058320" Enhanced Approved "Golgi apparatus,Actin filaments,Centrosome" "Secreted to blood" NA NA 2490000 320000 "Golgi apparatus, Actin filaments" Centrosome "CAB020801: , HPA049799: AB_2680889, HPA058320: AB_2732621" "unprognostic (1.18e-1)" "unprognostic (9.61e-2)" "unprognostic (1.56e-2)" "prognostic unfavorable (5.46e-5)" "unprognostic (1.91e-3)" "unprognostic (9.20e-2)" "unprognostic (2.42e-2)" "unprognostic (6.04e-3)" "unprognostic (1.11e-1)" "unprognostic (1.74e-1)" "unprognostic (7.64e-2)" "unprognostic (2.35e-1)" "prognostic unfavorable (5.46e-9)" "unprognostic (1.06e-2)" "unprognostic (1.21e-1)" "unprognostic (5.33e-2)" "unprognostic (3.69e-2)" 4.3 24.0 7.1 2.3 8.4 1.0 1.4 0.2 45.6 8.2 3.8 3.2 0.1 1.1 1.8 3.9 2.2 1.5 1.6 3.2 9.2 11.0 0.9 0.9 0.8 0.7 9.4 2.2 1.5 19.5 0.8 71.6 0.8 7.0 2.1 1.4 1.3 1.5 2.2 2.9 4.0 1.3 2.9 2.9 6.1 1.9 20.7 5.0 0.0 1.6 0.1 0.9 1.4 2.1 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.4 0.2 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 128.7 0.0 0.9 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.1 6.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 7.1 8.4 0.2 24.6 9.2 11.0 9.4 2.2 7.0 5.0 0.0 1.1 0.0 0.4 3.4 17.7 2.8 5.1 0.0 2.3 0.0 3.9 0.0 0.0 5.8 9.7 2.9 2.4 0.0 11.0 0.2 6.2 3.2 0.0 0.2 0.4 0.0 15.3 6.2 0.0 19.9 13.0 0.0 11.8 0.0 0.0 0.8 4.7 0.0 306.6 0.0 2.4 148.8 3.8 14.0 40.1 2.6 0.1 0.0 0.4 0.5 NRIP3 C11orf14 ENSG00000175352 "Nuclear receptor interacting protein 3" Q9NQ35 11 8980576-9004049 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "adrenal gland: 11.5;blood: 13.8;bone marrow: 12.7;brain: 28.4;testis: 30.3" "Group enriched" "Detected in many" 7 "Early spermatids: 432.1;Horizontal cells: 228.8;Late spermatids: 344.8;Spermatocytes: 110.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 7 "basophil: 13.8" "Lineage enriched" "Detected in many" 13 "granulocytes: 13.8" "Cell line enhanced" "Detected in many" "HBF TERT88: 14.4;HMC-1: 26.2;SiHa: 17.0;U-87 MG: 24.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058827, HPA072961" Approved Approved Cytosol NA NA Cytosol "HPA058827: AB_2683829, HPA072961: " "unprognostic (2.05e-1)" "unprognostic (1.42e-1)" "unprognostic (8.84e-3)" "unprognostic (5.43e-3)" "unprognostic (1.66e-1)" "unprognostic (2.68e-1)" "unprognostic (2.03e-4)" "unprognostic (1.25e-1)" "unprognostic (1.88e-1)" "unprognostic (3.63e-2)" "unprognostic (1.04e-2)" "unprognostic (1.11e-1)" "unprognostic (1.33e-1)" "unprognostic (1.13e-1)" "unprognostic (1.41e-1)" "unprognostic (5.88e-3)" "unprognostic (1.30e-1)" 2.9 11.5 10.0 2.0 19.7 12.7 4.8 27.6 24.7 1.9 1.0 3.1 0.0 1.0 3.9 3.8 1.4 2.1 2.2 1.4 28.4 9.6 1.2 0.7 1.3 1.3 10.5 6.8 0.8 0.8 2.4 0.7 1.3 11.0 1.2 1.2 3.3 1.1 1.4 0.6 0.9 1.0 2.8 4.5 1.0 1.6 30.3 0.8 0.0 1.4 0.0 1.1 1.0 0.3 0.1 0.2 13.8 0.3 0.1 1.0 0.2 0.0 0.4 0.9 0.1 0.4 1.4 0.0 10.2 4.0 8.2 8.7 1.5 0.9 0.0 1.5 2.9 4.9 0.1 2.7 0.2 14.4 0.7 4.0 1.1 0.5 0.1 0.6 12.7 26.2 1.9 0.1 8.5 0.1 8.7 6.6 2.2 2.0 0.1 7.5 0.0 0.6 4.1 3.3 0.0 0.0 0.0 1.4 0.0 0.1 0.6 2.7 0.8 17.0 0.5 2.6 0.7 1.7 1.2 8.3 12.7 6.0 0.7 0.0 0.0 0.0 0.0 24.5 1.5 6.1 13.8 0.1 2.0 0.1 0.3 0.2 0.1 0.5 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.0 1.0 0.2 10.0 19.7 27.6 19.6 28.4 9.6 10.5 6.8 11.0 0.8 0.0 2.2 0.0 4.8 1.9 6.7 1.2 0.0 0.0 0.0 0.0 9.8 0.4 5.0 0.4 432.1 1.4 0.0 0.0 1.0 0.4 1.2 2.6 15.1 0.0 12.7 228.8 5.1 0.0 1.5 344.8 6.4 5.2 3.3 1.0 0.0 4.1 4.8 0.0 5.3 0.0 9.8 0.0 2.1 110.3 37.3 0.9 0.8 0.0 0.0 3.4 PCSK1N "BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII" ENSG00000102109 "Proprotein convertase subtilisin/kexin type 1 inhibitor" Q9UHG2 X 48831094-48835633 "Predicted secreted proteins" Neuropeptide "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.9;kidney: 72.9;pituitary gland: 127.7" "Group enriched" "Detected in many" 5 "Intestinal endocrine cells: 2932.5;Proximal tubular cells: 1024.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "MAIT T-cell: 3.0;memory CD4 T-cell: 6.5;memory CD8 T-cell: 6.3;naive CD4 T-cell: 2.7;naive CD8 T-cell: 8.2;T-reg: 2.1" "Lineage enriched" "Detected in single" 77 "T-cells: 8.2" "Cell line enhanced" "Detected in some" "HEK 293: 20.0;PC-3: 50.7;SCLC-21H: 20.1;SH-SY5Y: 18.6;SiHa: 17.6;U-266/84: 23.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003925, HPA064734" Enhanced Supported Approved Vesicles "Secreted to blood" NA NA 5300000 Vesicles "HPA003925: AB_1079582, HPA064734: AB_2685339" "unprognostic (2.44e-3)" "unprognostic (5.86e-2)" "unprognostic (1.94e-1)" "prognostic unfavorable (1.15e-4)" "unprognostic (3.36e-1)" "unprognostic (4.76e-3)" "unprognostic (1.49e-2)" "unprognostic (3.34e-1)" "unprognostic (5.63e-2)" "unprognostic (3.55e-1)" "unprognostic (1.50e-3)" "unprognostic (2.79e-3)" "prognostic favorable (1.36e-4)" "unprognostic (3.34e-2)" "unprognostic (2.91e-2)" "unprognostic (1.91e-1)" "unprognostic (2.14e-1)" 4.1 27.5 49.1 2.6 72.7 2.1 2.2 15.6 70.3 3.2 9.8 10.8 1.5 12.4 4.4 10.9 2.1 2.3 2.8 2.7 38.5 74.9 72.9 2.1 2.6 2.2 33.5 29.0 2.2 20.0 12.4 127.7 2.3 32.9 4.6 2.7 6.6 2.8 3.1 2.2 2.8 8.5 2.7 18.3 2.4 26.0 3.8 9.8 0.0 2.2 0.0 2.1 2.1 0.5 0.1 0.0 0.0 0.0 0.0 8.2 0.8 0.0 1.8 0.0 5.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 1.8 0.0 0.0 3.6 0.0 1.4 0.2 0.0 0.3 0.0 0.0 20.0 0.0 0.0 3.0 0.0 0.0 1.2 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.1 2.7 0.0 50.7 0.0 0.0 0.1 0.4 0.0 20.1 18.6 17.6 0.0 1.4 0.2 0.0 0.0 0.0 0.0 7.8 0.0 1.6 4.6 23.4 0.1 0.1 0.0 0.5 0.0 0.0 0.0 1.1 0.0 3.0 0.0 6.5 6.3 0.0 0.1 2.7 8.2 0.0 0.0 0.0 0.0 2.1 0.8 49.1 72.7 15.6 70.3 38.5 74.9 33.5 29.0 32.9 9.8 0.0 0.0 2.2 1.5 14.1 134.7 1.0 5.1 1.4 0.0 369.9 49.1 0.5 235.4 7.5 11.6 0.5 12.9 0.0 0.6 43.5 6.2 36.6 0.0 0.0 1.5 413.2 2932.5 0.0 0.0 41.9 3.1 2.7 54.0 0.0 16.6 54.9 36.6 411.7 6.7 1024.2 101.7 0.0 16.5 18.2 20.6 10.0 1.6 3.2 10.1 2.6 PCSK2 "NEC2, PC2, SPC2" ENSG00000125851 "Proprotein convertase subtilisin/kexin type 2" P16519 20 17226107-17484578 "Enzymes, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 35.0;thyroid gland: 79.5" "Cell type enhanced" "Detected in many" 26 "Horizontal cells: 125.5;Melanocytes: 199.1;Muller glia cells: 518.9" "Group enriched" "Detected in many" 6 "pancreatic cancer: 14.6;thyroid cancer: 65.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 22 "basophil: 2.2" "Lineage enriched" "Detected in single" 22 "granulocytes: 2.2" "Group enriched" "Detected in some" 5 "AF22: 36.7;SCLC-21H: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049627 Approved Approved Vesicles "Secreted in other tissues" NA NA Vesicles "HPA049627: AB_2680835" "unprognostic (2.03e-3)" "unprognostic (1.61e-1)" "unprognostic (3.13e-1)" "unprognostic (2.18e-1)" "unprognostic (2.13e-1)" "unprognostic (6.84e-2)" "unprognostic (3.07e-3)" "unprognostic (4.31e-1)" "unprognostic (5.88e-2)" "unprognostic (2.50e-3)" "unprognostic (2.14e-1)" "unprognostic (7.26e-5)" "unprognostic (2.29e-1)" "unprognostic (1.57e-1)" "unprognostic (2.35e-1)" "unprognostic (1.14e-1)" 1.6 35.0 16.3 1.7 20.5 1.3 1.3 7.7 27.8 2.9 4.2 1.6 0.0 6.2 0.9 1.2 2.1 2.0 1.4 3.1 18.0 11.1 1.1 1.0 2.2 0.8 4.1 16.2 11.6 23.7 0.9 1.7 1.5 9.0 1.3 2.8 16.6 2.7 2.3 1.0 16.6 3.3 1.3 5.4 0.9 11.9 4.7 3.8 0.0 79.5 0.0 0.9 1.9 1.8 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 36.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 0.1 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.3 20.5 7.7 27.8 18.0 11.1 4.1 16.2 9.0 3.8 0.0 5.3 0.0 0.0 7.2 27.6 0.9 0.0 0.0 1.2 0.0 5.9 0.0 0.0 0.0 76.9 0.6 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 125.5 0.0 8.0 0.0 2.7 2.6 0.2 199.1 0.0 0.0 518.9 4.6 0.0 0.0 0.0 11.5 0.0 1.0 0.5 0.2 1.3 0.0 0.0 0.0 0.1 PENK ENSG00000181195 Proenkephalin P01210 8 56436674-56446734 "Plasma proteins, Predicted secreted proteins, Transporters" "Endorphin, Neuropeptide, Opioid peptide" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 124.3;brain: 171.5" "Cell type enhanced" "Detected in some" 32 "Leydig cells: 1053.7;Peritubular cells: 212.2;Spermatocytes: 309.0" "Cancer enhanced" "Detected in many" "lung cancer: 4.5" "Region enriched" "Detected in many" 12 "basal ganglia: 171.5" "Cell type enhanced" "Detected in some" "naive B-cell: 3.1" "Group enriched" "Detected in many" 19 "B-cells: 3.1;dendritic cells: 1.2;monocytes: 1.2" "Cell line enhanced" "Detected in some" "ASC diff: 16.6;ASC TERT1: 9.9;BJ: 9.2;THP-1: 8.6" "Region enriched" "Detected in all" 7 "basal ganglia: 3244.3" "Region enriched" "Detected in all" 7 "basal ganglia: 1049.6" "HPA013138, CAB016390" Enhanced "Secreted in other tissues" NA NA 35000 "CAB016390: AB_2161515, HPA013138: AB_1855191" "unprognostic (6.89e-2)" "unprognostic (1.21e-1)" "unprognostic (2.71e-2)" "unprognostic (1.17e-3)" "unprognostic (1.56e-2)" "unprognostic (3.58e-3)" "unprognostic (1.31e-2)" "unprognostic (3.60e-1)" "unprognostic (6.34e-2)" "unprognostic (5.73e-2)" "unprognostic (3.47e-2)" "unprognostic (4.24e-2)" "unprognostic (1.73e-3)" "unprognostic (1.11e-1)" "unprognostic (4.48e-2)" "unprognostic (3.98e-3)" 2.5 124.3 2.8 1.7 171.5 0.3 0.9 3.9 7.8 14.3 2.2 0.9 0.1 0.6 3.0 0.9 0.9 2.6 4.0 9.1 1.2 9.1 0.3 0.2 1.0 0.3 2.5 0.4 8.2 0.6 0.2 1.5 1.1 8.4 11.7 0.9 2.2 0.9 8.1 1.1 0.5 0.9 1.7 7.0 0.3 1.1 29.9 14.7 0.0 0.6 0.3 0.3 0.5 0.6 3.1 1.2 0.0 1.2 0.0 0.0 0.5 0.0 0.0 0.1 0.0 16.6 9.9 0.0 9.2 2.9 1.7 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 8.6 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.2 3.1 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.5 2.8 171.5 3.9 7.8 1.2 9.1 2.5 0.4 8.4 14.7 0.0 1.0 0.0 0.0 0.1 0.0 0.6 0.0 1.4 4.5 0.0 0.0 0.0 0.0 0.0 56.7 0.5 0.0 0.0 0.0 0.0 3.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 37.9 1053.7 0.3 0.0 0.0 0.0 0.0 0.0 0.0 212.2 0.0 0.0 6.5 0.4 309.0 17.5 0.4 0.0 0.0 0.0 0.0 PHOX2A "ARIX, CFEOM2, FEOM2, PMX2A" ENSG00000165462 "Paired like homeobox 2a" O14813 11 72239077-72245664 "Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 24.6;brain: 12.1;lymphoid tissue: 9.7" "Cell type enriched" "Detected in single" 9 "Spermatogonia: 3.6" "Cancer enriched" "Detected in some" 9 "ovarian cancer: 9.3" "Region enriched" "Detected in single" 96 "pons and medulla: 12.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 228 "SH-SY5Y: 115.5" "Region enriched" "Detected in single" 9 "pons and medulla: 0.8" "Not detected" "Not detected" "HPA053810, HPA065621, HPA078004" Enhanced Supported Nucleoplasm No NA Nucleoplasm "HPA053810: , HPA065621: AB_2685522, HPA078004: AB_2732367" "unprognostic (5.84e-2)" "unprognostic (8.51e-2)" "unprognostic (5.07e-2)" "unprognostic (2.19e-1)" "unprognostic (2.13e-1)" "unprognostic (9.92e-4)" "unprognostic (3.03e-2)" 0.4 24.6 0.0 9.7 0.0 0.0 0.0 0.0 0.1 0.2 3.3 0.5 0.0 0.4 0.1 0.0 1.4 0.1 0.3 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.8 0.0 12.1 0.9 0.7 1.7 0.7 3.7 0.0 0.0 3.2 0.3 2.1 0.1 1.6 5.2 0.0 0.0 0.0 0.0 0.0 2.6 0.6 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 115.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 PHOX2B "NBPhox, Phox2b, PMX2B" ENSG00000109132 "Paired like homeobox 2b" Q99453 4 41744082-41748970 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 14.5;brain: 24.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 99 "pons and medulla: 24.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 91 "SH-SY5Y: 53.6" "Region enriched" "Detected in single" 17 "pons and medulla: 5.9" "Region enriched" "Detected in single" 27 "pons and medulla: 2.0" "HPA074325, HPA074941" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "HPA074325: AB_2686678, HPA074941: AB_2732272" "unprognostic (1.01e-1)" "unprognostic (2.47e-1)" "unprognostic (5.27e-2)" 0.0 14.5 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.2 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.4 0.0 0.0 0.0 24.8 0.2 1.4 0.8 0.0 0.0 0.0 0.0 3.2 0.5 0.4 0.0 0.9 0.1 0.0 0.1 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 53.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 24.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PNMT PENT ENSG00000141744 "Phenylethanolamine N-methyltransferase" P11086 17 39667981-39670475 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Catecholamine biosynthesis" "Methyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 94.6;ductus deferens: 53.7;seminal vesicle: 40.7" "Cell type enhanced" "Detected in some" 12 "Cardiomyocytes: 12.2;Collecting duct cells: 5.2;Ito cells: 11.6" "Cancer enhanced" "Detected in many" "cervical cancer: 27.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "gdT-cell: 2.5" "Group enriched" "Detected in many" 5 "B-cells: 1.0;T-cells: 2.5" "Cell line enhanced" "Detected in some" "HEL: 4.9;K-562: 10.4;NB-4: 20.7;NTERA-2: 4.0;SCLC-21H: 5.6;SH-SY5Y: 5.2" "Region enhanced" "Detected in some" "basal ganglia: 1.3" "Not detected" "Not detected" "CAB017029, HPA043412, HPA051005" Enhanced NA NA "CAB017029: , HPA043412: AB_2630373, HPA051005: AB_2681306" "unprognostic (1.50e-1)" "unprognostic (3.74e-2)" "unprognostic (1.08e-1)" "prognostic unfavorable (3.95e-5)" "unprognostic (4.27e-2)" "unprognostic (3.02e-1)" "unprognostic (2.98e-2)" "unprognostic (5.75e-2)" "unprognostic (5.29e-2)" "unprognostic (1.30e-1)" "unprognostic (1.51e-1)" "unprognostic (1.33e-1)" "unprognostic (1.52e-4)" "unprognostic (1.58e-1)" "unprognostic (1.97e-1)" "unprognostic (4.72e-2)" "unprognostic (1.87e-2)" 2.3 94.6 3.9 0.8 13.8 1.6 5.4 0.9 3.0 1.3 1.9 1.5 53.7 0.9 1.0 2.7 0.9 1.9 0.8 4.9 1.7 5.4 1.0 0.7 1.6 0.8 9.1 1.5 0.9 0.7 2.4 12.9 2.4 3.6 4.3 0.7 0.9 0.7 40.7 10.5 0.8 1.0 0.8 0.7 0.9 0.9 1.3 2.7 0.0 0.7 0.8 0.7 1.3 1.7 1.0 0.0 0.3 0.3 0.0 2.5 0.3 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 1.4 4.9 0.1 0.4 2.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 20.7 4.0 0.4 0.0 0.1 0.0 0.3 0.0 0.0 5.6 5.2 0.0 2.2 0.1 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.5 0.0 0.4 1.0 0.4 1.5 0.0 0.4 0.0 0.7 0.3 0.0 0.3 0.0 0.0 0.3 3.9 13.8 0.9 3.0 1.7 5.4 9.1 1.5 3.6 2.7 0.0 0.0 0.0 0.6 0.5 0.4 12.2 2.5 0.0 0.0 5.2 0.0 0.0 1.7 0.0 0.6 2.8 0.0 0.0 0.0 0.6 0.0 0.2 0.0 0.0 0.1 0.0 2.9 11.6 0.0 0.9 2.0 0.0 0.0 0.0 0.1 2.8 0.1 0.0 0.4 0.0 0.4 0.0 0.3 0.3 2.1 0.4 0.0 0.0 0.2 1.6 PRPH "NEF4, PRPH1" ENSG00000135406 Peripherin P41219 12 49293252-49298686 "Predicted intracellular proteins" "Amyotrophic lateral sclerosis, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 44.9;testis: 30.4" "Group enriched" "Detected in some" 5 "Early spermatids: 268.2;Late spermatids: 616.9" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in some" 23 "pons and medulla: 44.9" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "AN3-CA: 91.5" "Group enriched" "Detected in many" 4 "hypothalamus: 22.7;pons and medulla: 36.8" "Low region specificity" "Detected in all" "CAB002437, HPA039277, HPA063887" Enhanced NA NA "CAB002437: AB_563956, HPA039277: AB_2676424, HPA063887: AB_2685142" "unprognostic (1.73e-2)" "unprognostic (3.03e-1)" "unprognostic (1.11e-1)" "unprognostic (1.87e-1)" "prognostic unfavorable (7.88e-4)" "unprognostic (5.04e-3)" "unprognostic (1.88e-2)" "unprognostic (6.29e-2)" "unprognostic (1.87e-1)" "unprognostic (2.10e-1)" "unprognostic (7.38e-2)" "unprognostic (1.24e-1)" "unprognostic (4.25e-3)" "unprognostic (3.63e-2)" "unprognostic (5.73e-2)" "unprognostic (4.86e-3)" "unprognostic (6.36e-5)" 2.2 20.0 0.7 13.4 1.6 0.1 1.2 0.5 2.3 3.9 16.0 0.6 1.0 5.6 0.9 1.4 3.1 2.5 2.7 3.2 1.9 0.9 0.3 0.1 0.7 0.4 0.9 0.0 0.5 1.1 0.3 2.5 0.5 44.9 5.0 2.7 12.1 1.0 4.9 0.6 0.7 11.4 2.5 5.9 0.9 4.8 30.4 0.4 0.1 0.3 0.9 0.2 5.8 7.0 0.0 0.0 0.0 0.0 0.0 0.8 0.2 0.0 0.1 0.0 91.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.3 0.0 0.6 0.1 0.0 0.3 19.7 0.3 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.7 1.6 0.5 0.5 1.9 0.9 0.9 0.0 44.9 0.4 0.0 0.0 0.0 0.0 0.0 8.5 0.3 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 268.2 0.1 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.1 23.8 88.5 0.0 0.0 616.9 5.5 0.0 0.0 0.0 0.2 10.2 0.1 0.0 1.8 0.4 19.9 0.0 7.2 11.2 7.7 0.4 0.0 0.0 0.1 0.1 PTPRN "IA-2, ICA512" ENSG00000054356 "Protein tyrosine phosphatase, receptor type N" Q16849 2 219289623-219309648 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" Receptor "Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 89.6;pancreas: 28.9;pituitary gland: 43.4" "Group enriched" "Detected in some" 13 "Bipolar cells: 48.9;Cone photoreceptor cells: 56.9;Horizontal cells: 92.2;Intestinal endocrine cells: 45.2;Rod photoreceptor cells: 31.1" "Group enriched" "Detected in some" 12 "glioma: 5.3;pancreatic cancer: 18.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "U-2 OS: 20.3;U-87 MG: 75.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007152, HPA007179" Enhanced Approved "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "HPA007152: AB_2667759, HPA007179: AB_1079714" "unprognostic (1.43e-1)" "unprognostic (1.33e-4)" "unprognostic (2.91e-3)" "unprognostic (5.83e-3)" "prognostic unfavorable (1.45e-7)" "unprognostic (3.64e-2)" "unprognostic (1.24e-4)" "unprognostic (1.58e-3)" "unprognostic (1.02e-1)" "unprognostic (6.20e-4)" "unprognostic (1.44e-2)" "unprognostic (1.54e-1)" "unprognostic (2.28e-10)" "unprognostic (1.43e-2)" "unprognostic (2.49e-1)" "unprognostic (1.10e-2)" "unprognostic (8.61e-2)" 1.7 22.3 19.3 4.7 35.7 1.7 1.3 17.3 89.6 1.2 2.4 2.5 0.0 2.5 1.5 1.2 1.5 1.3 1.5 1.4 21.6 40.1 1.5 1.2 1.4 1.3 14.4 19.8 1.3 28.9 1.2 43.4 1.4 22.0 1.4 1.9 3.1 1.2 1.3 1.2 2.0 2.5 2.4 3.5 1.3 6.0 1.4 2.1 0.0 1.5 0.0 1.2 2.7 0.0 0.1 0.3 0.2 0.0 0.0 0.6 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.0 0.3 1.3 2.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.6 0.0 0.1 2.5 0.0 6.2 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 3.2 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 20.3 0.0 0.0 0.0 0.0 0.2 75.5 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.3 0.1 0.0 0.4 0.2 0.0 0.0 0.0 0.6 3.7 19.3 35.7 17.3 54.0 21.6 40.1 14.4 19.8 22.0 2.1 0.0 0.0 0.0 0.1 0.1 48.9 1.7 0.0 0.0 0.0 0.0 56.9 0.0 1.7 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.0 0.0 0.1 92.2 45.2 0.0 0.0 0.2 0.3 0.0 1.7 0.0 0.0 4.1 4.3 0.0 0.0 0.0 31.1 0.0 0.3 2.2 2.3 0.1 0.0 0.0 0.0 0.0 PTPRN2 "IA-2beta, ICAAR, KIAA0387, phogrin" ENSG00000155093 "Protein tyrosine phosphatase, receptor type N2" Q92932 7 157539056-158587788 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Phospholipid metabolism" "Hydrolase, Protein phosphatase, Receptor" "Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 40.6;pancreas: 51.3" "Cell type enhanced" "Detected in many" 7 "Ciliated cells: 84.3;Intestinal endocrine cells: 126.1" "Cancer enhanced" "Detected in all" "prostate cancer: 40.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 14.8" "Lineage enriched" "Detected in all" 4 "granulocytes: 14.8" "Cell line enhanced" "Detected in some" "AF22: 15.6;HDLM-2: 22.0;NB-4: 22.6;SCLC-21H: 12.5;SH-SY5Y: 12.7;THP-1: 11.1;U-87 MG: 15.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006900, HPA007255, HPA026656" Enhanced Approved Vesicles NA NA Vesicles "HPA006900: AB_1079715, HPA007255: , HPA026656: AB_1855912" "unprognostic (2.42e-1)" "unprognostic (4.17e-2)" "unprognostic (7.82e-2)" "unprognostic (2.69e-2)" "prognostic unfavorable (9.37e-5)" "unprognostic (7.12e-3)" "unprognostic (1.04e-1)" "unprognostic (4.55e-2)" "unprognostic (4.27e-2)" "unprognostic (1.64e-1)" "unprognostic (1.20e-2)" "unprognostic (1.39e-1)" "prognostic favorable (8.68e-4)" "unprognostic (2.60e-2)" "unprognostic (1.48e-1)" "unprognostic (1.43e-3)" "unprognostic (6.16e-2)" 2.1 10.5 20.1 1.7 33.9 1.0 1.1 6.2 40.6 1.7 4.6 2.9 0.0 5.1 2.0 2.9 1.5 6.9 4.7 1.9 18.2 21.3 2.0 1.2 3.1 2.1 11.3 22.3 5.8 51.3 0.5 20.0 1.5 10.3 10.2 3.7 1.5 3.4 2.6 0.8 0.7 4.2 1.6 5.3 7.7 24.2 2.2 5.2 0.0 5.6 0.3 1.7 2.8 0.6 3.4 1.3 14.8 1.1 1.5 3.5 1.1 0.0 0.2 15.6 1.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.6 0.2 3.7 0.0 0.4 0.0 0.0 22.0 0.2 0.0 0.0 2.5 0.6 0.0 0.0 1.1 0.2 0.0 0.1 0.1 0.0 1.1 0.0 0.1 0.0 0.2 6.5 22.6 3.1 5.5 0.8 0.0 0.7 0.1 0.0 0.0 12.5 12.7 0.0 0.0 0.0 0.0 0.0 11.1 3.3 5.1 1.9 0.0 0.4 0.1 0.0 0.0 15.4 9.2 3.7 8.7 1.1 1.6 0.9 0.1 0.3 2.3 1.5 1.1 1.3 3.4 1.4 0.9 14.8 1.5 0.0 0.2 3.5 1.1 20.1 33.9 6.2 40.6 18.2 21.3 11.3 22.3 10.3 5.2 3.0 11.7 10.4 12.5 2.1 31.6 2.2 7.6 84.3 13.6 38.4 9.8 0.4 29.9 15.8 35.1 23.3 4.5 0.0 11.7 0.4 3.9 21.1 18.5 0.8 34.3 11.1 126.1 41.1 11.0 13.1 11.5 6.0 11.8 3.6 39.6 40.1 6.1 5.8 18.4 3.5 6.3 25.8 5.1 41.6 11.7 1.3 0.6 10.0 7.2 22.5 QPCT "GCT, QC" ENSG00000115828 "Glutaminyl-peptide cyclotransferase" Q16769 2 37344574-37373322 "Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acyltransferase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 77.6;blood: 137.6" "Group enriched" "Detected in many" 6 "Intestinal endocrine cells: 208.4;Melanocytes: 501.0" "Cancer enhanced" "Detected in all" "melanoma: 97.4" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "neutrophil: 137.6" "Lineage enriched" "Detected in many" 5 "granulocytes: 137.6" "Cell line enhanced" "Detected in many" "BJ hTERT+: 17.9;SCLC-21H: 24.3;SK-MEL-30: 81.6;U-266/84: 63.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008406 Enhanced Approved Cytosol "Secreted to blood" NA NA Cytosol "HPA008406: AB_1855981" "unprognostic (6.25e-3)" "unprognostic (6.69e-2)" "unprognostic (4.95e-2)" "unprognostic (1.44e-1)" "unprognostic (1.44e-2)" "unprognostic (9.32e-2)" "unprognostic (1.13e-3)" "unprognostic (9.73e-2)" "unprognostic (2.71e-3)" "unprognostic (7.86e-2)" "unprognostic (3.67e-2)" "unprognostic (1.17e-1)" "unprognostic (6.78e-2)" "unprognostic (7.76e-3)" "unprognostic (1.21e-1)" "unprognostic (9.48e-3)" "unprognostic (3.62e-3)" 3.2 77.6 4.3 5.4 5.8 17.0 6.4 1.2 11.6 9.2 11.3 2.2 1.5 2.2 6.2 43.7 2.4 1.9 5.5 2.9 6.7 17.9 12.4 1.3 6.1 7.4 3.9 5.0 1.4 5.5 9.6 31.6 7.8 5.9 3.5 4.2 21.2 14.7 2.8 4.0 14.2 2.3 3.4 3.0 8.5 3.4 2.6 0.5 2.3 1.8 4.4 4.8 7.0 2.9 0.2 10.7 137.6 29.7 0.0 0.0 12.1 0.1 8.0 0.0 0.0 1.1 2.7 0.0 1.1 17.9 1.3 2.1 0.5 1.4 0.0 0.6 6.0 15.2 0.0 0.5 0.0 2.1 0.1 15.6 3.6 0.0 1.5 0.1 0.5 0.0 1.5 0.0 9.9 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.8 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.1 8.8 2.2 24.3 0.0 1.3 0.0 81.6 1.6 0.1 0.6 3.8 0.0 0.0 0.0 0.1 3.1 63.8 0.0 5.5 0.0 0.0 0.6 29.7 0.2 0.0 3.4 0.0 0.2 0.0 0.0 10.7 0.1 0.0 0.0 137.6 0.0 0.3 0.2 0.0 12.1 4.3 5.8 1.2 11.6 6.7 17.9 3.9 5.0 5.9 0.5 3.0 2.9 8.2 9.7 34.7 10.9 1.1 2.5 1.4 0.0 21.0 2.0 0.5 1.7 45.4 0.4 7.3 2.0 0.0 2.1 4.3 11.0 9.5 55.3 0.2 21.3 41.3 208.4 22.7 29.2 2.2 2.8 35.6 501.0 10.8 5.8 1.2 25.4 1.9 22.3 4.7 2.9 12.9 15.5 2.1 0.6 12.7 3.9 1.9 6.9 5.5 REEP6 "C19orf32, DP1L1, FLJ25383, Yip2f" ENSG00000115255 "Receptor accessory protein 6" Q96HR9 19 1490747-1497927 "Disease related genes, Predicted membrane proteins" "Disease mutation, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 90.8;liver: 119.0;testis: 71.2" "Cell type enriched" "Detected in many" 5 "Late spermatids: 2546.7" "Cancer enhanced" "Detected in all" "liver cancer: 114.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 16.1;Hep G2: 15.4;K-562: 42.7;T-47d: 35.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA003895, HPA048015" Enhanced Supported "Endoplasmic reticulum" NA NA 26000 "Endoplasmic reticulum" "HPA003895: AB_1845723, HPA048015: AB_2680233" "unprognostic (1.21e-1)" "unprognostic (1.56e-1)" "unprognostic (7.76e-2)" "unprognostic (1.63e-3)" "unprognostic (3.24e-1)" "unprognostic (2.43e-2)" "unprognostic (1.92e-1)" "unprognostic (6.85e-2)" "unprognostic (7.38e-2)" "unprognostic (4.56e-1)" "unprognostic (1.49e-1)" "unprognostic (1.93e-1)" "unprognostic (1.40e-2)" "unprognostic (2.17e-1)" "unprognostic (8.08e-2)" "unprognostic (2.83e-1)" "unprognostic (5.38e-2)" 2.4 20.1 4.1 0.7 5.9 0.6 3.9 3.1 6.0 1.4 41.7 2.8 4.4 60.2 1.0 5.7 2.7 1.4 7.6 0.9 4.5 1.9 6.1 119.0 0.6 0.7 2.6 2.1 1.7 10.1 0.5 2.2 0.7 2.1 4.9 0.7 27.4 5.6 11.8 0.7 1.7 90.8 1.1 1.6 0.6 1.3 71.2 1.1 0.3 1.6 1.1 2.1 3.2 1.2 1.0 4.2 0.1 4.8 5.8 7.1 2.3 2.0 2.5 0.8 10.5 1.6 0.5 11.7 0.5 0.1 0.5 0.5 16.1 6.6 1.1 3.7 0.3 0.7 2.1 2.7 0.1 0.2 0.5 1.1 6.1 0.3 15.4 1.2 0.4 2.0 1.3 1.1 0.0 0.3 0.9 0.3 1.4 42.7 1.5 0.1 8.1 0.5 1.3 3.9 5.9 5.7 1.6 0.3 2.7 3.0 0.9 0.2 5.8 2.8 4.1 1.7 0.4 35.7 1.6 0.9 0.8 1.7 2.5 0.4 5.1 1.4 0.1 3.6 2.6 2.3 0.0 1.5 0.0 7.1 1.7 3.8 0.1 2.1 1.5 2.5 1.0 2.8 3.2 0.1 5.8 4.8 4.2 2.0 2.3 4.1 5.9 3.1 6.0 4.5 1.9 2.6 2.1 2.1 1.1 3.0 2.7 3.4 6.8 6.1 23.2 1.6 86.6 5.3 6.8 5.2 31.4 55.0 6.6 28.9 512.6 2.8 17.0 0.0 61.1 7.5 2.5 15.7 10.3 229.1 8.2 22.3 5.8 4.3 5.7 2546.7 31.7 4.3 28.7 1.8 10.4 27.6 24.6 6.0 15.6 36.0 217.9 19.4 2.6 24.2 30.4 5.8 30.1 5.1 11.0 11.2 RGN "RC, SMP30" ENSG00000130988 Regucalcin Q15493 X 47078355-47093314 "Enzymes, Plasma proteins, Predicted intracellular proteins" Hydrolase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 51.0;liver: 118.8" "Cell type enhanced" "Detected in many" 13 "Distal tubular cells: 49.7;Hepatocytes: 141.5;Muller glia cells: 48.0;Peritubular cells: 65.4;Proximal tubular cells: 86.9" "Cancer enriched" "Detected in many" 6 "liver cancer: 47.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 16.5;fHDF/TERT166: 5.3;Hep G2: 24.6" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA029102, HPA029103, HPA029104" Enhanced Approved Cytosol NA NA 47000 Cytosol "HPA029102: AB_10599846, HPA029103: AB_10602097, HPA029104: " "unprognostic (1.80e-1)" "unprognostic (1.25e-1)" "unprognostic (1.39e-1)" "unprognostic (5.56e-3)" "unprognostic (8.22e-3)" "unprognostic (1.32e-2)" "prognostic favorable (7.55e-4)" "unprognostic (2.60e-3)" "unprognostic (2.23e-2)" "unprognostic (8.38e-2)" "unprognostic (3.37e-2)" "unprognostic (1.14e-2)" "prognostic favorable (5.10e-10)" "unprognostic (1.69e-2)" "unprognostic (2.43e-1)" "unprognostic (7.82e-2)" "unprognostic (5.22e-2)" 2.6 51.0 6.7 0.6 6.5 0.4 1.5 8.4 6.2 2.8 1.9 6.2 2.5 4.5 2.3 6.1 1.5 1.7 2.0 4.5 6.1 4.2 17.6 118.8 4.9 0.7 5.9 4.5 7.5 12.7 6.2 2.5 4.2 5.0 4.8 1.1 8.4 7.5 6.3 3.8 0.6 4.6 4.9 4.4 1.1 2.9 1.5 5.2 0.0 6.5 1.6 0.6 2.1 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.2 0.4 0.3 0.6 0.0 0.0 16.5 0.0 0.0 0.9 5.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 24.6 0.8 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 6.7 6.5 8.4 6.2 6.1 4.2 5.9 4.5 5.0 5.2 6.0 2.2 0.0 2.9 0.5 10.2 25.8 7.6 2.7 1.2 14.0 0.0 0.1 49.7 8.4 0.4 1.8 0.0 0.0 7.9 0.1 7.5 0.9 0.0 141.5 0.1 4.8 4.6 6.2 4.0 0.6 23.0 0.0 1.7 0.0 0.0 48.0 7.8 0.0 65.4 86.9 1.9 12.9 8.0 0.2 0.2 0.3 0.2 0.0 0.3 1.1 RIMS2 "KIAA0751, OBOE, RAB3IP3, RIM2" ENSG00000176406 "Regulating synaptic membrane exocytosis 2" Q9UQ26 8 103500748-104256094 "Predicted intracellular proteins" Differentiation "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 51.1;brain: 28.7" "Group enriched" "Detected in many" 10 "Bipolar cells: 397.4;Cone photoreceptor cells: 665.6;Rod photoreceptor cells: 1047.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "AF22: 6.0;Daudi: 11.7;RT4: 8.4;SCLC-21H: 20.8;SuSa: 8.3" "Low region specificity" "Detected in all" "HPA046538, HPA066498, CAB079049" Enhanced Supported Approved "Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" "CAB079049: , HPA046538: , HPA066498: AB_2685678" "unprognostic (2.98e-2)" "unprognostic (7.14e-2)" "unprognostic (4.47e-2)" "unprognostic (5.51e-2)" "unprognostic (2.82e-1)" "unprognostic (7.09e-3)" "unprognostic (2.02e-2)" "unprognostic (1.16e-2)" "unprognostic (7.61e-2)" "unprognostic (8.01e-3)" "unprognostic (1.40e-2)" "unprognostic (6.34e-2)" "unprognostic (1.67e-5)" "unprognostic (8.12e-4)" "unprognostic (1.04e-1)" "unprognostic (1.61e-1)" "unprognostic (9.08e-2)" 0.9 51.1 15.8 1.0 21.8 1.1 1.8 14.5 28.7 8.5 0.9 0.5 0.9 1.2 1.4 1.7 1.0 6.3 1.7 0.9 10.3 4.9 1.1 0.9 1.0 1.1 3.1 17.5 2.8 1.6 0.9 12.4 1.1 8.6 2.8 1.0 5.8 1.0 1.8 1.0 1.0 1.4 2.0 4.0 0.9 1.7 3.9 8.7 0.0 2.9 0.0 1.0 1.5 1.6 0.7 0.7 2.9 0.6 1.6 0.6 0.2 3.7 0.0 6.0 0.0 0.0 0.0 0.0 0.4 0.3 1.1 1.4 0.1 0.3 11.7 0.1 0.0 1.2 0.3 1.8 0.7 1.9 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.9 2.1 0.0 1.3 0.1 0.5 0.0 0.5 0.8 0.0 4.6 0.0 0.6 0.0 0.0 0.0 0.0 8.4 20.8 5.1 0.0 0.1 0.5 8.3 0.3 0.2 0.0 0.0 5.6 0.1 0.1 1.5 0.0 0.1 0.4 0.2 0.2 2.7 0.6 0.6 0.6 0.3 0.4 0.4 0.3 0.4 0.1 0.7 0.3 0.5 2.9 1.6 0.4 0.7 0.3 0.2 15.8 21.8 14.5 28.7 10.3 4.9 3.1 17.5 8.6 8.7 26.8 32.3 0.0 1.6 0.2 397.4 0.7 2.5 18.7 29.6 0.0 665.6 0.5 1.7 0.0 29.0 0.5 0.0 0.0 0.0 0.2 0.8 4.9 15.1 0.0 0.2 63.5 8.1 0.6 0.3 13.5 66.7 0.4 1.7 0.0 0.2 71.8 0.4 0.0 27.6 0.1 1047.7 0.0 0.3 15.3 9.9 0.4 0.1 0.5 0.0 0.9 SCARB1 "CD36L1, CLA-1, CLA1, SR-BI, SRB1" ENSG00000073060 "Scavenger receptor class B member 1" Q8WTV0 12 124776856-124882668 "Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 173.1;liver: 93.7;placenta: 65.9" "Cell type enhanced" "Detected in many" 8 "Hepatocytes: 105.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 24.9" "Group enriched" "Detected in many" 5 "dendritic cells: 24.9;monocytes: 6.5" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA066285, CAB070124, HPA072449" Enhanced Approved "Vesicles,Lysosomes,Rods & Rings" NA NA Vesicles "Lysosomes, Rods & Rings" "CAB070124: AB_10107658, HPA066285: AB_2685649, HPA072449: AB_2732201" "unprognostic (9.70e-3)" "unprognostic (4.94e-3)" "unprognostic (1.32e-1)" "unprognostic (4.79e-2)" "unprognostic (1.65e-3)" "unprognostic (4.21e-3)" "prognostic unfavorable (1.83e-5)" "prognostic unfavorable (4.02e-4)" "unprognostic (2.30e-1)" "unprognostic (1.09e-1)" "unprognostic (1.80e-2)" "unprognostic (4.99e-2)" "prognostic unfavorable (1.49e-5)" "unprognostic (3.50e-1)" "unprognostic (1.49e-1)" "unprognostic (1.81e-1)" "unprognostic (4.13e-1)" 21.2 173.1 7.9 3.5 21.4 1.8 25.0 4.3 10.1 4.7 28.6 13.4 1.1 8.8 4.3 3.5 2.8 4.7 8.0 3.2 7.4 5.1 2.2 93.7 5.8 5.3 6.3 5.1 14.3 2.9 3.3 4.4 65.9 9.4 4.3 4.9 10.7 8.6 2.3 3.0 6.3 21.3 4.4 5.7 5.0 2.7 7.7 11.4 0.5 4.0 1.1 5.6 3.6 10.0 3.1 24.9 1.2 6.5 0.2 0.4 2.5 9.3 22.6 7.4 29.1 4.9 10.5 0.0 6.6 7.5 8.2 5.2 27.0 29.9 27.0 19.0 4.4 13.4 14.2 18.8 44.3 3.9 12.9 18.9 7.6 22.4 43.5 16.6 13.0 6.6 17.9 9.0 15.6 11.1 14.0 22.3 4.9 14.3 11.6 1.5 18.5 4.0 17.4 6.7 11.6 23.4 16.9 5.9 53.9 0.7 13.1 13.9 5.4 35.8 48.4 33.5 4.5 27.1 14.7 2.1 1.3 8.8 6.6 10.1 2.7 1.1 4.4 5.3 15.8 12.8 0.0 6.5 0.0 0.2 3.7 0.2 3.1 0.1 0.4 8.2 1.7 0.1 0.1 1.2 0.2 0.5 24.9 0.0 2.5 7.9 21.4 4.3 10.1 7.4 5.1 6.3 5.1 9.4 11.4 3.0 2.4 18.5 3.1 4.9 5.0 4.8 12.7 4.0 1.2 3.5 27.5 8.8 3.3 5.1 13.9 11.2 9.2 23.3 6.6 9.3 5.9 10.5 1.1 105.2 42.5 15.9 10.3 15.4 14.0 10.8 8.3 10.1 45.5 5.4 14.0 52.5 5.9 14.2 4.9 2.4 7.4 0.0 2.1 27.8 1.7 2.8 36.3 2.5 8.8 3.8 SCG2 "CHGC, SgII, SN" ENSG00000171951 "Secretogranin II" P13521 2 223596940-223602503 "Plasma proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 133.0;brain: 94.1;pituitary gland: 76.5" "Group enriched" "Detected in some" 8 "Bipolar cells: 124.4;Intestinal endocrine cells: 272.8" "Group enriched" "Detected in many" 8 "glioma: 70.0;pancreatic cancer: 52.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 25.5;HSkMC: 21.8;hTERT-RPE1: 21.8;SCLC-21H: 22.2;SH-SY5Y: 9.7;WM-115: 16.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011893, HPA075062" Enhanced Supported Approved "Golgi apparatus,Vesicles" "Secreted to blood" NA NA 54000 "Golgi apparatus" Vesicles "HPA011893: AB_1856656, HPA075062: AB_2732277" "unprognostic (2.93e-2)" "unprognostic (1.44e-2)" "unprognostic (1.23e-3)" "unprognostic (6.82e-4)" "unprognostic (2.51e-2)" "unprognostic (1.13e-2)" "unprognostic (2.77e-3)" "unprognostic (6.73e-2)" "unprognostic (1.08e-1)" "unprognostic (4.69e-2)" "prognostic favorable (5.58e-4)" "unprognostic (1.34e-1)" "prognostic unfavorable (7.01e-10)" "unprognostic (2.47e-3)" "unprognostic (4.02e-1)" "unprognostic (1.57e-2)" "unprognostic (1.90e-3)" 3.5 133.0 13.3 11.0 94.1 0.9 0.9 5.6 55.9 1.4 5.4 5.8 0.0 17.3 2.1 0.9 1.0 0.8 2.2 1.4 10.5 79.4 1.0 0.8 1.9 0.9 21.7 11.0 1.3 10.7 1.1 76.5 1.1 57.7 2.1 5.5 1.5 0.9 1.3 0.8 1.0 8.0 5.2 10.3 0.8 8.0 0.9 5.0 0.0 3.1 0.0 0.8 1.1 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.3 4.8 4.0 1.1 25.5 0.1 0.2 0.9 1.8 4.7 0.2 0.4 0.0 0.4 0.3 2.9 0.1 0.1 0.0 2.4 0.0 0.2 0.0 0.2 0.0 0.3 0.3 2.1 21.8 0.1 2.7 0.9 21.8 0.0 0.0 0.1 0.2 2.3 0.1 0.0 0.1 3.4 0.0 0.0 0.0 0.1 0.0 0.3 0.0 22.2 9.7 0.0 0.2 1.1 0.8 0.0 0.0 0.0 2.5 1.0 0.1 1.6 0.0 0.0 0.1 0.7 0.0 16.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 13.3 94.1 5.6 23.0 10.5 79.4 21.7 11.0 57.7 5.0 6.0 0.0 0.0 0.2 0.0 124.4 0.2 0.0 1.4 2.3 0.0 2.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.2 2.9 0.0 0.0 0.1 7.9 272.8 1.3 0.8 0.0 0.6 0.0 1.7 0.0 0.7 11.9 24.2 2.9 0.4 0.0 12.7 0.0 0.5 0.1 0.2 0.1 0.1 0.0 0.3 0.6 SLC18A1 "CGAT, VAT1, VMAT1" ENSG00000036565 "Solute carrier family 18 member A1" P54219 8 20144855-20183206 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 25.4;intestine: 10.8" "Cell type enriched" "Detected in some" 37 "Intestinal endocrine cells: 133.5" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.8" "Region enriched" "Detected in single" 4 "midbrain: 2.0" "Group enriched" "Detected in some" 12 "intermediate monocyte: 2.3;non-classical monocyte: 6.0" "Lineage enriched" "Detected in single" 18 "monocytes: 6.0" "Cell line enriched" "Detected in some" 8 "SH-SY5Y: 39.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA006877, HPA063797" Enhanced NA NA "HPA006877: AB_2667690, HPA063797: AB_2685125" "unprognostic (8.03e-4)" "unprognostic (1.02e-1)" "unprognostic (3.75e-3)" "unprognostic (3.50e-1)" "unprognostic (6.61e-2)" "unprognostic (3.09e-3)" "unprognostic (1.67e-1)" "unprognostic (2.16e-2)" "unprognostic (3.45e-2)" "unprognostic (1.48e-1)" "unprognostic (1.32e-3)" "unprognostic (1.61e-1)" "unprognostic (2.48e-2)" "unprognostic (8.25e-2)" "unprognostic (4.41e-2)" "unprognostic (2.06e-1)" "unprognostic (1.05e-1)" 0.0 25.4 0.2 0.8 0.1 0.0 0.0 0.0 0.2 0.2 8.8 1.3 1.3 1.4 0.4 0.0 0.0 0.0 0.7 0.1 0.1 0.4 0.0 0.0 0.0 0.0 2.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 1.0 2.7 0.0 0.0 2.8 0.0 0.0 10.8 0.0 0.1 0.3 1.1 0.2 0.0 0.2 0.2 0.0 0.1 1.3 0.4 0.0 0.3 0.2 6.0 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 2.2 39.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 6.0 0.0 0.0 0.3 0.2 0.1 0.0 0.2 0.1 0.4 2.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 133.5 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 SLC18A2 "SVAT, SVMT, VMAT2" ENSG00000165646 "Solute carrier family 18 member A2" Q05940 10 117241073-117279430 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 26.3;brain: 28.3;cervix, uterine: 31.2" "Cell type enriched" "Detected in some" 22 "granulocytes: 603.6" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 10 "hypothalamus: 9.0;midbrain: 28.3;pons and medulla: 26.5" "Cell type enriched" "Detected in some" 13 "basophil: 26.3" "Lineage enriched" "Detected in many" 13 "granulocytes: 26.3" "Cell line enriched" "Detected in some" 20 "HMC-1: 91.2" "Region enhanced" "Detected in many" "midbrain: 75.4" "Group enriched" "Detected in all" 5 "midbrain: 143.8;pons and medulla: 34.7" HPA073224 Enhanced Approved Vesicles,Centrosome NA NA "Vesicles, Centrosome" "HPA073224: AB_2732222" "unprognostic (1.49e-1)" "unprognostic (2.48e-1)" "unprognostic (2.33e-3)" "unprognostic (9.00e-2)" "unprognostic (2.85e-1)" "unprognostic (5.33e-3)" "unprognostic (2.23e-1)" "unprognostic (1.71e-2)" "unprognostic (1.40e-1)" "unprognostic (4.55e-2)" "unprognostic (2.00e-1)" "unprognostic (6.06e-3)" "unprognostic (7.94e-5)" "unprognostic (2.95e-2)" "unprognostic (2.31e-1)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" 1.7 13.9 1.7 3.1 2.0 2.0 2.0 1.7 1.6 31.2 2.3 0.5 2.2 1.5 11.2 4.9 3.0 1.1 15.9 1.0 1.9 9.0 1.1 3.3 7.6 1.5 28.3 0.2 9.7 3.7 0.5 1.6 2.1 26.5 10.8 3.4 3.1 1.0 4.0 1.1 5.8 2.5 5.4 2.9 0.5 3.5 1.5 0.3 14.1 0.6 3.4 2.9 3.1 5.4 0.0 2.0 26.3 0.0 0.0 0.3 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 4.6 0.0 0.0 0.0 0.2 91.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.1 0.1 0.0 0.1 0.4 0.0 26.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.0 0.0 2.0 0.0 1.1 1.7 2.0 1.7 1.6 1.9 9.0 28.3 0.2 26.5 0.3 8.9 27.6 0.0 0.0 1.6 0.6 0.2 0.0 1.4 4.5 0.0 3.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 4.4 603.6 0.0 0.7 0.0 8.5 11.6 1.8 0.0 0.6 0.6 1.7 0.0 0.0 0.3 0.1 0.0 4.6 0.0 0.7 0.0 0.2 0.2 0.1 2.4 0.0 0.0 0.0 0.0 SLC35G2 "DKFZp564K2464, MGC3295, TMEM22" ENSG00000168917 "Solute carrier family 35 member G2" Q8TBE7 3 136818647-136855892 "Predicted membrane proteins, Transporters" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Early spermatids: 36.2;Endothelial cells: 26.0;Ito cells: 26.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "gdT-cell: 1.6;memory CD8 T-cell: 3.5;naive CD8 T-cell: 2.4" "Lineage enriched" "Detected in single" 16 "T-cells: 3.5" "Cell line enhanced" "Detected in many" "BJ hTERT+: 34.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052054, HPA064728" Approved Supported "Plasma membrane" NA NA "Plasma membrane" "HPA052054: AB_2681709, HPA064728: AB_2685336" "unprognostic (1.04e-1)" "unprognostic (1.46e-2)" "unprognostic (6.91e-4)" "unprognostic (2.56e-4)" "unprognostic (5.34e-2)" "unprognostic (6.73e-2)" "unprognostic (1.16e-5)" "unprognostic (1.83e-3)" "unprognostic (1.12e-1)" "unprognostic (6.39e-2)" "unprognostic (1.49e-2)" "unprognostic (3.32e-1)" "prognostic unfavorable (1.16e-7)" "unprognostic (1.00e-2)" "unprognostic (1.69e-1)" "unprognostic (1.07e-2)" "unprognostic (2.30e-2)" 20.2 24.6 10.6 3.7 12.0 1.3 18.3 16.6 17.4 8.1 3.6 6.4 6.6 2.2 6.7 8.1 4.1 5.0 8.7 7.6 11.6 15.2 4.3 7.1 6.0 3.3 10.9 10.5 5.3 13.3 6.7 15.9 11.7 11.3 4.8 3.8 3.2 2.7 4.8 2.8 3.0 2.4 8.5 12.4 3.1 3.1 17.2 4.9 0.9 8.8 2.1 2.5 8.2 9.3 0.2 0.0 0.0 0.1 0.0 3.5 0.3 1.7 4.9 5.0 2.2 10.1 8.2 0.0 7.8 34.1 11.7 17.7 4.6 2.6 0.0 6.0 8.0 18.7 0.6 5.9 0.3 10.9 0.0 1.6 1.4 6.0 2.8 12.9 0.0 0.0 11.6 0.9 10.2 2.8 8.6 8.7 3.1 0.8 0.0 14.9 0.0 2.1 1.5 1.1 0.0 3.7 1.8 3.3 0.0 10.0 0.4 8.3 5.5 6.3 0.0 10.7 1.8 0.0 0.8 5.9 8.7 2.2 3.8 8.4 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.1 0.0 1.6 0.0 0.5 0.0 0.1 3.5 0.0 0.2 0.1 2.4 0.0 0.0 0.0 0.0 0.0 0.3 10.6 12.0 16.6 17.0 11.6 15.2 10.9 10.5 11.3 4.9 11.9 6.5 2.7 3.7 3.0 5.4 2.0 0.0 1.4 10.3 1.8 11.8 1.0 1.7 2.7 36.2 26.0 0.5 0.0 9.3 1.1 11.0 3.3 2.3 1.8 0.6 6.4 4.1 26.4 1.0 19.8 9.2 3.5 3.3 3.6 0.6 6.8 9.1 0.0 2.8 0.4 4.7 6.5 7.2 22.7 9.4 2.6 1.8 4.8 0.6 1.8 SLC6A2 "NAT1, NET, NET1, SLC6A5" ENSG00000103546 "Solute carrier family 6 member 2" P23975 16 55655604-55706192 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 20.4;placenta: 41.8" "Group enriched" "Detected in some" 5 "Early spermatids: 3.2;Extravillous trophoblasts: 6.9;Late spermatids: 3.7;Spermatocytes: 10.4;Syncytiotrophoblasts: 4.7" "Cancer enhanced" "Detected in some" "liver cancer: 1.9" "Region enriched" "Detected in single" 27 "pons and medulla: 9.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 30 "SH-SY5Y: 107.1" "Region enriched" "Detected in some" 4 "pons and medulla: 8.2" "Region enriched" "Detected in single" 32 "pons and medulla: 23.1" "HPA004057, HPA076311, CAB078195" Enhanced Supported Approved Mitochondria,Cytosol NA NA Cytosol Mitochondria "CAB078195: AB_2665806, HPA004057: AB_1080012, HPA076311: AB_2732307" "unprognostic (9.58e-3)" "unprognostic (5.48e-2)" "unprognostic (1.26e-4)" "unprognostic (4.07e-1)" "unprognostic (4.16e-1)" "unprognostic (8.38e-2)" "unprognostic (2.97e-2)" "unprognostic (3.29e-1)" "unprognostic (2.31e-1)" "unprognostic (3.27e-1)" "unprognostic (2.12e-2)" "unprognostic (2.95e-2)" "unprognostic (1.72e-1)" "unprognostic (6.02e-2)" "unprognostic (8.48e-2)" "unprognostic (1.43e-2)" 2.4 20.4 0.3 0.1 0.1 0.0 1.8 0.1 0.3 3.2 0.3 0.3 0.1 0.0 4.5 7.2 0.8 0.4 0.4 0.1 0.1 0.0 0.4 1.0 0.5 0.1 0.1 0.1 0.2 0.1 0.0 0.1 41.8 9.7 0.5 0.1 0.1 1.6 1.7 0.1 11.4 0.4 1.0 0.2 0.1 0.2 8.3 0.2 0.1 0.2 0.9 0.5 0.5 1.7 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.8 107.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.1 0.3 0.1 0.0 0.1 0.1 9.7 0.2 0.0 0.0 0.0 0.1 1.3 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 3.2 0.0 0.0 0.0 0.0 6.9 0.4 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.4 0.1 0.4 4.7 0.0 0.0 0.0 SOAT1 "ACAT, SOAT, STAT" ENSG00000057252 "Sterol O-acyltransferase 1" P35610 1 179293714-179358680 "Enzymes, FDA approved drug targets, Predicted membrane proteins" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism" "Acyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 87.4" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009533, HPA047171" Enhanced Enhanced "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "CAB009533: AB_633499, HPA047171: AB_2679967" "unprognostic (3.29e-2)" "unprognostic (7.60e-2)" "unprognostic (1.11e-1)" "unprognostic (3.21e-2)" "unprognostic (2.83e-1)" "unprognostic (1.81e-3)" "unprognostic (7.81e-3)" "unprognostic (3.29e-1)" "unprognostic (9.00e-2)" "unprognostic (9.84e-2)" "unprognostic (1.06e-1)" "unprognostic (5.45e-3)" "unprognostic (7.02e-3)" "unprognostic (4.67e-3)" "unprognostic (9.64e-2)" "unprognostic (4.67e-2)" "unprognostic (1.82e-1)" 23.9 87.4 4.1 8.3 5.7 7.0 9.6 2.9 4.0 6.8 7.2 5.6 7.8 5.5 8.2 6.0 3.4 8.3 9.8 5.7 5.5 4.1 12.1 8.8 18.6 13.0 6.2 2.3 10.8 15.5 8.1 14.6 11.6 4.9 13.1 6.9 9.6 51.1 8.9 4.1 5.8 7.0 7.5 10.5 13.6 8.1 6.8 4.9 4.0 6.2 2.9 7.2 9.4 8.7 6.6 24.3 19.8 26.8 18.5 16.0 14.8 20.4 9.6 7.9 11.7 30.9 16.9 42.5 9.9 17.5 22.0 25.7 9.8 23.4 11.6 15.7 18.0 26.8 7.5 25.1 5.9 23.8 13.2 5.2 5.4 8.1 10.2 12.7 9.2 2.1 13.3 3.8 25.7 22.1 9.3 9.4 14.3 11.6 6.0 34.2 4.3 9.8 3.0 3.8 3.3 3.2 12.2 10.3 6.8 19.4 12.8 2.4 6.2 15.3 6.5 5.7 9.8 6.8 6.3 8.9 26.2 12.6 28.6 21.8 8.5 31.0 9.9 10.4 5.0 48.5 19.6 26.8 0.7 14.0 17.0 13.5 6.6 13.1 13.1 24.3 5.5 12.7 12.6 19.8 18.5 11.1 4.4 16.0 14.8 4.1 5.7 2.9 4.0 5.5 4.1 6.2 2.3 4.9 4.9 20.8 33.1 10.4 8.5 8.9 7.2 5.6 22.9 48.2 14.8 19.2 13.7 14.8 1.7 33.4 19.5 13.0 7.9 0.0 21.9 46.9 18.6 33.8 13.9 21.9 69.5 6.4 57.5 21.5 66.9 10.8 30.2 63.1 21.9 44.1 27.7 6.8 20.1 10.5 24.4 12.8 13.0 25.8 13.0 5.6 8.2 4.5 7.3 27.9 16.8 6.5 SPTBN4 "KIAA1642, SPTBN3" ENSG00000160460 "Spectrin beta, non-erythrocytic 4" Q9H254 19 40466241-40576464 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin capping, Actin-binding" "Deafness, Disease mutation, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 36.3" "Cell type enhanced" "Detected in some" 12 "Bipolar cells: 55.4;Cone photoreceptor cells: 53.0;Horizontal cells: 69.9;Rod photoreceptor cells: 67.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "K-562: 3.5;Karpas-707: 5.1;SCLC-21H: 8.0;SH-SY5Y: 4.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054481 Enhanced Approved Nucleoplasm,Nucleoli NA NA Nucleoli Nucleoplasm "HPA054481: AB_2682502" "unprognostic (1.97e-3)" "unprognostic (1.02e-1)" "unprognostic (5.65e-4)" "unprognostic (3.72e-4)" "unprognostic (7.79e-3)" "unprognostic (9.77e-2)" "unprognostic (2.62e-1)" "unprognostic (2.50e-2)" "unprognostic (3.19e-2)" "unprognostic (1.65e-1)" "unprognostic (1.78e-4)" "unprognostic (4.54e-1)" "unprognostic (2.55e-2)" "unprognostic (6.79e-2)" "unprognostic (1.42e-1)" "unprognostic (1.85e-2)" "unprognostic (2.02e-1)" 3.1 5.9 13.4 1.2 15.3 1.2 1.2 36.3 27.1 1.4 1.3 1.8 0.0 1.7 2.3 1.3 1.6 2.0 1.8 3.3 9.8 10.8 1.9 1.3 1.2 1.0 7.5 13.0 4.1 3.0 3.3 8.0 1.0 10.4 2.8 1.1 2.6 2.2 2.0 5.1 1.3 1.5 1.8 2.8 1.3 2.5 3.5 3.7 0.0 1.6 0.0 1.0 1.2 0.5 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.6 0.0 0.2 0.1 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.4 2.3 2.0 0.4 0.1 0.0 0.0 0.0 0.0 0.4 2.4 0.5 0.0 0.0 0.3 0.0 0.8 0.3 0.0 0.0 0.0 0.1 0.0 0.3 3.5 5.1 0.0 1.3 0.0 0.0 0.2 0.3 0.9 0.5 0.0 1.1 0.0 0.0 8.0 4.9 0.1 0.2 0.0 0.1 0.7 0.0 0.0 0.0 1.5 0.8 0.0 0.2 0.3 0.3 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.4 15.3 36.3 22.7 9.8 10.8 7.5 13.0 10.4 3.7 0.0 0.0 0.0 0.1 0.1 55.4 4.4 0.0 0.0 0.0 0.0 53.0 0.0 0.0 0.1 3.5 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.8 0.2 69.9 15.6 0.6 0.3 0.9 7.5 0.0 1.7 1.0 0.3 4.7 0.2 0.0 6.7 1.4 67.0 0.0 0.9 3.2 4.6 0.4 0.0 0.0 0.2 0.1 SST SMST ENSG00000157005 Somatostatin P61278 3 187668906-187670399 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 102.8;intestine: 105.2;pancreas: 105.6;stomach 1: 90.4" "Cell type enriched" "Detected in some" 213 "Intestinal endocrine cells: 1353.8" "Group enriched" "Detected in many" 7 "ovarian cancer: 249.9;pancreatic cancer: 1039.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "EFO-21: 15.6;U-2 OS: 29.0;U-251 MG: 4.8;U-698: 6.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000075, HPA019472, CAB034105" Enhanced Supported "Secreted to blood" NA NA "CAB000075: AB_2688022, CAB034105: AB_2271061, HPA019472: AB_1857360" "unprognostic (2.44e-1)" "unprognostic (2.05e-1)" "prognostic unfavorable (1.93e-5)" "unprognostic (5.12e-3)" "unprognostic (1.54e-2)" "unprognostic (4.69e-1)" "unprognostic (3.31e-2)" "unprognostic (8.16e-3)" "unprognostic (1.63e-1)" "unprognostic (1.07e-3)" "unprognostic (8.47e-2)" "unprognostic (4.19e-1)" "unprognostic (3.27e-1)" "unprognostic (1.45e-1)" 2.0 13.0 28.6 1.9 53.8 1.7 0.7 0.1 47.9 0.7 45.1 1.8 21.9 105.2 0.9 0.7 1.1 0.7 1.0 0.9 17.5 102.8 2.5 0.7 0.7 1.0 6.2 15.4 0.8 105.6 0.7 1.5 0.7 16.1 1.5 7.4 0.4 0.7 7.5 0.7 3.1 36.1 1.4 18.4 0.7 90.4 0.7 8.6 0.0 0.9 0.0 0.7 4.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.6 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.2 0.3 0.0 0.0 0.0 1.5 0.0 0.1 0.0 0.0 29.0 0.3 4.8 0.0 1.7 6.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.6 53.8 0.1 47.9 17.5 102.8 6.2 15.4 16.1 8.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.2 0.0 2.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 1353.8 0.0 0.0 0.0 0.0 0.0 0.0 6.4 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.2 0.0 STAR "StAR, STARD1" ENSG00000147465 "Steroidogenic acute regulatory protein" P49675 8 38143649-38151265 "Disease related genes, Predicted intracellular proteins" "Lipid transport, Steroidogenesis, Transport" "Congenital adrenal hyperplasia, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 311.3;ovary: 124.6" "Cell type enriched" "Detected in some" 5 "Leydig cells: 46.3" "Cancer enhanced" "Detected in some" "testis cancer: 3.0" "Region enriched" "Detected in some" 8 "basal ganglia: 10.6" "Cell type enriched" "Detected in single" 11 "basophil: 5.7" "Lineage enriched" "Detected in single" 11 "granulocytes: 5.7" "Cell line enriched" "Detected in some" 5 "K-562: 101.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "HPA023644, HPA027318, CAB032598" Enhanced NA NA "CAB032598: AB_2115937, HPA023644: AB_10598916, HPA027318: AB_10601574" "unprognostic (1.60e-4)" "unprognostic (3.20e-2)" "unprognostic (9.17e-2)" "unprognostic (3.28e-2)" "unprognostic (9.22e-2)" "unprognostic (1.32e-3)" "unprognostic (1.96e-2)" "unprognostic (2.12e-5)" "unprognostic (3.30e-2)" "unprognostic (2.36e-1)" "unprognostic (1.77e-3)" "unprognostic (6.65e-2)" "unprognostic (4.75e-9)" "unprognostic (1.58e-1)" "unprognostic (1.33e-1)" "unprognostic (9.48e-2)" "unprognostic (6.16e-2)" 0.2 311.3 0.5 0.3 10.6 0.3 0.0 0.0 1.0 0.0 0.0 11.6 0.0 0.0 0.1 0.8 0.2 0.4 0.0 0.1 0.3 0.5 0.0 0.0 0.0 0.3 0.2 0.9 124.6 0.0 0.0 0.2 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.2 0.4 0.0 0.0 29.5 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.3 0.1 5.7 0.1 0.0 0.5 0.1 0.0 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 21.9 0.1 1.3 0.3 1.0 0.0 3.5 0.0 0.0 0.0 0.2 0.0 0.0 101.9 0.0 0.0 0.0 0.0 12.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 12.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 5.7 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.2 0.3 0.0 0.0 0.0 0.5 0.1 0.5 10.6 0.0 1.0 0.3 0.5 0.2 0.9 1.2 0.1 0.0 0.0 0.0 0.6 8.4 1.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 5.6 46.3 0.0 3.3 0.0 0.0 0.5 0.1 0.0 3.9 0.0 0.7 0.0 0.2 1.4 0.7 9.8 0.1 0.0 0.0 0.1 TH DYT5b ENSG00000180176 "Tyrosine hydroxylase" P07101 11 2163929-2171877 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Catecholamine biosynthesis, Neurotransmitter biosynthesis" "Monooxygenase, Oxidoreductase" "Disease mutation, Dystonia, FDA approved drug targets, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 31 "adrenal gland: 83.5;brain: 41.4" "Cell type enhanced" "Detected in some" 21 "Collecting duct cells: 1.8;Extravillous trophoblasts: 7.9;Leydig cells: 3.1;Syncytiotrophoblasts: 1.8" "Cancer enhanced" "Detected in some" "urothelial cancer: 4.0" "Group enriched" "Detected in many" 6 "hypothalamus: 15.5;midbrain: 41.4;pons and medulla: 41.2" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 32 "PC-3: 35.9;SK-BR-3: 12.8" "Region enhanced" "Detected in many" "olfactory region: 220.1" "Region enriched" "Detected in many" 19 "midbrain: 692.0" "CAB002522, HPA013768, HPA014010, HPA061003, CAB072340" Enhanced Supported Approved Cytosol NA NA Cytosol "CAB002522: AB_564047, CAB072340: , HPA013768: , HPA014010: , HPA061003: AB_2630374" "unprognostic (1.31e-1)" "unprognostic (1.30e-1)" "unprognostic (9.08e-2)" "unprognostic (1.75e-4)" "unprognostic (8.82e-3)" "unprognostic (5.88e-2)" "unprognostic (1.93e-1)" "unprognostic (1.74e-3)" "unprognostic (3.83e-2)" "unprognostic (4.39e-4)" "unprognostic (4.97e-1)" "unprognostic (3.61e-2)" "unprognostic (1.92e-1)" "unprognostic (1.60e-1)" "unprognostic (2.43e-1)" "unprognostic (2.70e-2)" "unprognostic (2.18e-2)" 1.3 83.5 0.0 0.3 5.4 0.2 0.2 0.0 0.7 1.8 0.2 6.2 0.0 0.2 0.3 0.3 0.2 0.3 0.4 0.2 0.3 15.5 0.2 0.2 0.2 0.2 41.4 0.0 0.3 0.3 0.2 0.2 0.9 41.2 0.6 0.2 0.3 0.2 2.0 0.2 0.5 0.4 0.2 0.0 0.3 0.2 0.3 1.5 0.0 0.2 0.0 0.2 0.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.3 35.9 0.0 0.0 0.0 0.1 0.0 0.7 0.1 0.0 12.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.7 0.3 15.5 41.4 0.0 41.2 1.5 0.0 0.0 0.0 0.1 0.1 0.0 0.8 0.0 0.0 0.0 1.8 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 7.9 0.4 0.0 0.0 0.0 0.4 0.0 0.0 1.3 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.8 0.0 0.0 0.1 VAT1L KIAA1576 ENSG00000171724 "Vesicle amine transport 1 like" Q9HCJ6 16 77788530-77980107 "Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 57.3;brain: 47.1;retina: 32.1" "Group enriched" "Detected in some" 15 "Horizontal cells: 281.3;Muller glia cells: 83.1" "Cancer enhanced" "Detected in many" "glioma: 7.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "myeloid DC: 1.1" "Lineage enhanced" "Detected in single" "dendritic cells: 1.1" "Cell line enhanced" "Detected in some" "AF22: 9.4;BJ hTERT+: 27.7;fHDF/TERT166: 15.1;NTERA-2: 32.6;U-87 MG: 34.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA044061, CAB046032, HPA061138" Enhanced Approved Cytosol NA NA Cytosol "CAB046032: AB_11126308, HPA044061: AB_10959610, HPA061138: " "unprognostic (1.49e-2)" "unprognostic (8.74e-3)" "unprognostic (8.80e-3)" "unprognostic (3.39e-2)" "unprognostic (3.62e-2)" "unprognostic (1.70e-2)" "unprognostic (2.39e-3)" "unprognostic (1.37e-1)" "unprognostic (1.86e-1)" "unprognostic (7.65e-2)" "unprognostic (8.57e-3)" "unprognostic (2.46e-1)" "prognostic unfavorable (3.01e-6)" "unprognostic (2.50e-2)" "unprognostic (6.53e-2)" "unprognostic (1.19e-1)" "unprognostic (5.96e-2)" 1.1 57.3 7.9 3.0 41.3 1.2 1.0 28.4 20.1 1.3 3.4 5.7 0.0 2.4 1.8 6.3 2.0 1.4 3.8 12.7 3.8 47.1 5.3 1.4 0.9 1.0 8.4 12.7 0.9 2.1 0.6 1.5 2.0 27.2 0.8 5.2 32.1 0.9 1.0 0.6 0.6 3.1 2.6 15.4 0.7 1.7 2.1 5.8 0.0 2.0 0.0 2.4 1.4 0.4 0.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.4 0.0 3.2 0.0 0.0 1.1 27.7 0.3 0.3 0.0 0.0 0.0 0.0 15.1 0.2 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.3 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 32.6 0.0 0.0 0.7 0.0 0.0 0.0 0.0 1.2 1.5 0.0 0.4 0.0 6.0 0.0 7.3 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 34.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.9 41.3 28.4 9.1 3.8 47.1 8.4 12.7 27.2 5.8 0.0 0.0 0.0 0.0 0.0 7.2 8.7 5.1 0.0 0.0 0.0 0.0 0.0 1.7 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 281.3 2.9 0.0 0.0 2.3 0.0 0.0 0.0 1.0 0.0 83.1 0.1 0.0 0.0 0.0 11.8 0.0 0.4 0.0 0.2 0.0 0.2 0.0 0.0 0.0 VGF "SCG7, SgVII" ENSG00000128564 "VGF nerve growth factor inducible" O15240 7 101162509-101165593 "Plasma proteins, Predicted secreted proteins" "Antibiotic, Antimicrobial, Growth factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 59.4;pituitary gland: 30.4" "Group enriched" "Detected in many" 7 "Horizontal cells: 212.9;Intestinal endocrine cells: 123.0" "Cancer enriched" "Detected in many" 6 "melanoma: 236.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "SH-SY5Y: 36.7;SK-MEL-30: 99.1;U-2 OS: 18.0;WM-115: 29.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA055177, HPA072505" Enhanced Enhanced "Golgi apparatus,Vesicles" "Secreted to blood" NA NA 1270000 2800000 "Golgi apparatus, Vesicles" "HPA055177: AB_2682728, HPA072505: AB_2686528" "unprognostic (3.04e-2)" "unprognostic (3.45e-1)" "unprognostic (3.19e-3)" "prognostic unfavorable (4.25e-4)" "prognostic unfavorable (3.31e-4)" "unprognostic (1.51e-2)" "unprognostic (2.86e-2)" "unprognostic (1.66e-3)" "unprognostic (2.25e-2)" "unprognostic (8.77e-2)" "unprognostic (3.84e-3)" "unprognostic (3.70e-3)" "unprognostic (9.82e-3)" "unprognostic (3.79e-1)" "unprognostic (7.23e-2)" "unprognostic (4.36e-3)" "unprognostic (2.21e-1)" 3.8 3.1 10.9 2.3 25.2 1.3 1.1 1.3 59.4 1.1 1.5 1.3 0.0 1.3 2.2 1.1 1.1 1.1 1.2 1.2 12.2 51.0 1.4 1.1 1.1 1.1 3.9 22.8 1.1 6.2 1.1 30.4 1.2 41.2 1.2 1.2 0.5 1.1 1.1 1.1 1.4 1.3 1.5 6.6 1.2 3.6 1.4 0.5 0.0 1.2 0.0 1.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.2 2.0 0.0 0.0 2.2 0.1 0.0 0.0 0.0 0.5 0.1 0.0 0.6 0.0 0.3 0.2 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.4 0.0 4.7 0.0 0.4 3.7 0.2 0.4 0.1 0.0 0.0 0.0 0.0 3.0 36.7 0.0 0.1 99.1 0.2 0.1 0.0 0.0 0.0 18.0 0.0 0.4 0.0 0.1 0.9 2.9 0.0 29.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.9 25.2 1.3 59.4 12.2 51.0 3.9 22.8 41.2 0.5 0.0 0.0 0.0 1.0 1.3 8.5 2.4 0.0 0.0 0.0 0.0 0.0 1.3 24.9 0.3 0.0 0.3 1.3 0.0 0.0 6.3 0.2 2.8 0.0 0.0 0.5 212.9 123.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.1 1.4 9.5 2.9 0.0 1.0 4.5 0.0 0.2 0.2 4.2 1.9 1.1 0.0 0.9 0.5 ZBTB8B "DKFZp547H154, RP1-27O5.1, ZNF916B" ENSG00000273274 "Zinc finger and BTB domain containing 8B" Q8NAP8 1 32465069-32496686 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 10.8" "Cell type enhanced" "Detected in many" 6 "Cone photoreceptor cells: 5.9" "Cancer enhanced" "Detected in single" "testis cancer: 0.5" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "RT4: 3.6;SCLC-21H: 3.6" HPA055553 Enhanced NA NA "HPA055553: AB_2682848" "unprognostic (8.32e-4)" "unprognostic (1.23e-1)" "unprognostic (3.83e-1)" "unprognostic (3.83e-5)" "unprognostic (1.86e-2)" "unprognostic (5.65e-2)" "unprognostic (1.67e-4)" "unprognostic (1.57e-2)" "unprognostic (5.94e-2)" "unprognostic (3.43e-3)" "unprognostic (9.08e-3)" "unprognostic (1.35e-1)" "unprognostic (2.93e-2)" "unprognostic (3.44e-2)" "unprognostic (6.11e-2)" "unprognostic (3.26e-3)" "unprognostic (5.88e-3)" 0.4 1.3 5.1 0.6 2.8 2.5 0.6 2.2 5.0 0.4 0.3 1.3 0.7 0.5 1.2 1.3 0.7 0.7 0.6 0.4 3.3 4.7 0.6 0.6 0.5 0.9 2.6 2.7 1.0 0.8 1.0 10.8 0.7 4.1 0.8 0.4 0.2 1.7 0.5 3.4 1.7 0.5 0.5 1.6 0.8 0.5 3.1 1.6 0.0 0.8 0.0 0.6 1.0 0.4 1.4 1.2 3.2 0.8 1.3 0.7 0.2 0.2 0.1 2.0 1.5 0.2 0.5 0.6 0.2 0.1 0.7 0.6 0.2 0.5 0.4 0.7 0.1 1.1 0.7 2.3 0.2 0.5 0.7 2.4 0.3 0.7 0.4 0.0 0.3 0.4 0.2 0.2 0.5 0.0 0.4 0.2 0.2 0.2 0.9 0.1 0.3 0.3 0.6 2.1 0.1 0.9 0.3 0.2 0.3 0.4 3.6 3.6 2.1 1.3 0.5 0.2 2.9 0.4 0.3 0.9 0.5 0.4 0.6 0.3 0.7 0.7 0.4 0.5 0.4 0.4 3.2 0.8 1.0 0.6 0.5 0.6 0.8 0.6 0.5 0.3 1.4 0.7 0.7 2.9 1.3 0.7 1.2 0.5 0.2 5.1 2.8 2.2 5.0 3.3 4.7 2.6 2.7 4.1 1.6 0.0 2.6 0.0 0.8 1.4 2.9 0.6 0.0 2.7 1.2 0.0 5.9 1.5 0.0 0.0 1.5 0.7 0.0 0.0 0.0 1.0 0.8 0.7 3.5 0.2 0.3 3.2 0.0 1.3 0.3 1.0 0.6 1.5 1.7 0.0 0.0 1.3 0.0 0.0 0.0 0.0 1.7 0.0 0.3 1.9 1.2 0.5 0.2 1.0 0.0 0.7